Document:

Amended and Restated License Agreement

 EXHIBIT 10.18 
 CONFIDENTIAL PROVISIONS REDACTED 
 AMENDED AND RESTATED 
 LICENSE AGREEMENT 
 This Agreement, dated as of
April 25, 2007 (“2007 Effective Date”), is by and between (i) SciClone Pharmaceuticals, Inc. (“SciClone”), a Delaware corporation having its principal place of business at 901 Mariners Island Blvd., San Mateo,
California 94404, and (ii) RESprotect GmbH, a German corporation having an office at Fiedlerstr. 34, D-01307 Dresden, GERMANY (hereinafter “RESprotect”). 
 RECITALS 
 WHEREAS, RESprotect possesses certain intellectual property rights related to RP101
((E)-5-(2-bromovinyl-)2’-deoxyuridine – also known as BVDU); and 
 WHEREAS, Resistys INC., having an office at 2121 Avenue of the
Stars, Suite 2550, Los Angeles, California 90067 including any Affiliates of Resistys (“Resistys”), Australian Cancer Technology Limited, an Australian corporation having an office at Aurora Place, Suite 4, Level 36, 88 Philip Street,
Sydney 2000, Australia including any Affiliates of ACT, and RESprotect GmbH, entered into a license agreement, effective as of September 13, 2004 (“2004 License Agreement”) and, effective on the same date, Resistys and RESprotect
entered into a supply agreement for Clinical Trial Material related to the 2004 License Agreement (“2004 Supply Agreement”); 
 WHEREAS, effective May 31, 2005, Australian Cancer Technology, Ltd. underwent a name change to “Avantogen Limited” (“Avantogen”); 
 WHEREAS, effective August 30, 2004, Resistys, was formed as a wholly-owned subsidiary of Avantogen for the principal purpose of entering into the 2004 License Agreement and 2004 Supply Agreement and, after
several share transfers, the sole shareholder of Resistys is now Avantogen Oncology Ltd (“AOI”); 
 WHEREAS, Resistys and
Avantogen, immediately prior to the entering into this Agreement assigned their respective interest in the 2004 License Agreement and the 2004 Supply Agreement to SciClone as of the 2007 Effective Date; 
 WHEREAS, SciClone desires to engage in research, development, marketing, sale and distribution of BVDU; and 
 WHEREAS, SciClone desires to acquire from RESprotect, and RESprotect is willing to grant to SciClone, an exclusive license in the Territory, as
hereinafter defined, under RESprotect’s intellectual property rights relating to BVDU, including patents and know-how, upon the terms and conditions set forth herein. 
 WHEREAS, on March 15, 2007, RESprotect, Resistys, Avantogen , AOI and SciClone, signed a non-binding Term Sheet (the “March 2007 Term
Sheet”) agreeing to complete certain definitive agreements by the 2007 Effective Date, including: (1) an assignment by Resistys and Avantogen to SciClone of the (a) 2004 License Agreement; (b) all assets owned or controlled by
them 

					
		  		  	CONFIDENTIAL TREATMENT

 
related to the 2004 License Agreement or the RP101 program, including, without limitation, all (i) intellectual property rights, including inventions
and know-how, whether or not patentable, (ii) data and information, (iii) regulatory filings, and (iv) agreements; (2) an assignment by Resistys to SciClone of the 2004 Supply Agreement; and (3) an agreement between
Resistys/AOI and RESprotect relating to certain consideration to be paid by Resistys/ AOI to RESprotect and (4) this Agreement and the 2007 Supply Agreement between RESprotect and SciClone. 
 NOW, therefore, in consideration of the promises and mutual covenants herein, RESprotect and SciClone hereby amend and restate the 2004 License Agreement
in its entirety to read in full as follows: 
 ARTICLE I 
 GENERAL DEFINITIONS 
 SECTION 1.1 The term “2007 Effective Date” shall mean the date set
forth in the first and opening paragraph of this Agreement. The term “2004 Effective Date” shall mean the Effective Date of the 2004 License Agreement which was September 13, 2004. 
 SECTION 1.2 The term “2007 Supply Agreement” shall mean the Supply Agreement between RESprotect and SciClone concluded with equal date as this
Agreement. 
 SECTION 1.3 The term “Affiliate” shall mean any corporation or other entity, which directly or indirectly controls, is
controlled by or is under common control with a party to this Agreement. A corporation or other entity shall be regarded as in control of another corporation or entity if it owns or directly or indirectly controls more than [****] of the voting
stock or other ownership interest of the other corporation or entity, or if it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the corporation or other entity or the power to elect or
appoint [****] or more of the members of the governing body of the corporation or other entity. 
 SECTION 1.4 The term “API” shall mean
active pharmaceutical ingredient. 
 SECTION 1.5 The term “Asia” shall mean the countries listed under “Asia” in Exhibit A.

 SECTION 1.6 The term “Clinical Trial Costs” shall mean [****]. 
 SECTION 1.7 The term “Development” shall have the meaning set forth under Section 4.1(a). 
 SECTION
1.8 The term “Development Plan” shall have the meaning set forth under Section 4.1(a). 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	2	  	CONFIDENTIAL TREATMENT

 SECTION 1.9 The term “Europe” shall mean the countries listed under “Europe” in
Exhibit A. 
 SECTION 1.10 The term “FDA” shall mean the United States Food and Drug Administration and its successor agencies,
if any. 
 SECTION 1.11 The term “First Commercial Sale” shall mean the first sale of Licensed Product by SciClone, and/or it’s
Sublicensees. 
 SECTION 1.12 The term “Grant-Back License” shall have the meaning set forth in Section 8.1. 
 SECTION 1.13 The term “Improvements” shall mean any amendments, modifications of and additions to the RESprotect Patent Rights and RESprotect Know-How
which are made, developed, reduced to practice or acquired by RESprotect during the term of this Agreement, including, but not limited to, such that: (i) improve the performance or efficacy of the Licensed Product, (ii) reduce any side
effects, drug interactions or other adverse effects of the Licensed Product, (iii) reduce the cost and/or increase the efficiency or productivity of the manufacturing and production processes for the Product, or (iv) increase
bio-availability or improve drug delivery. 
 SECTION 1.14 The term “Initiation of a Phase II Trial” shall mean the date when the first
patient is enrolled in a Phase II Trial. 
 SECTION 1.15 The term “Joint Technology” shall mean any inventions made jointly by employees of
SciClone or any of its Sublicensees and RESprotect or any of its Affiliates and/or it’s Other Licensees. 
 SECTION 1.16 The term
“License” shall have the meaning set forth in Section 2.1. 
 SECTION 1.17 The term “Licensed Finished Product” shall mean
the finished form medicinal product including the Licensed Product. 
 SECTION 1.18 The term “Licensed IP Rights” shall mean, collectively,
the RESprotect Patent Rights and the RESprotect Know-How. 
 SECTION 1.19 The term “Licensed Product” shall mean the API RP101 ((E)-5-(2-
bromovinyl-)2’-deoxyuridine—also known as BVDU), a salt of BVDU or a prodrug of BDVU (if developed by RESprotect) for use under the RESprotect Patent Rights, (i) which incorporates, embodies, utilizes or is based on RESprotect
Know-How or (ii) the manufacture, use, importation or sale of which would, but for the rights granted hereunder, constitute infringement of a Valid Claim under the RESprotect Patent Rights. 
 SECTION 1.20 The term “Market Sales” shall mean with regard to all sales of Licensed Product in the Territory, the gross amount invoiced for sales of
Licensed Product only and does not include any amounts invoiced to customers for customs duties or sales taxes directly related to the sale of Licensed Product, or for transportation, shipping and insurance costs. 
  

					
		  	3	  	CONFIDENTIAL TREATMENT

 SECTION 1.21 The term “Net Sales” shall mean with respect to all sales of Licensed Product by SciClone
or Sublicensees in the Territory, the gross invoiced sales price of Licensed Product less [****]. 
 SECTION 1.22 The term “Other Licensee”
shall mean any Third Party who receives a license from RESprotect under the RESprotect Patent Rights and RESprotect Know-How in relation to the Licensed Product for the territory of Europe and/ or Asia. 
 SECTION 1.23 The term “Patent Rights” shall mean the rights under any patent applications, issued patents and any and all substitutions, divisions,
continuations, continuations-in-part, reissues, renewals, reexaminations or extensions that have issued or in the future issue from such patent applications, including utility model and design patents and certificates of invention as well as any
patent term extensions, such as pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 and any foreign equivalents. 
 SECTION 1.24 The term “Phase II Trial” shall mean a phase II clinical trial as defined by the FDA rules and regulations. 
 SECTION 1.25 The term “Preclinical and Clinical Data” shall have the meaning set forth in Article V. 
 SECTION 1.26 The
term “RESprotect Know-How” shall mean any of RESprotect’s confidential proprietary information and materials relating to the research, development, manufacture, approval, marketing, use or sale of Licensed Product which during the
term of this Agreement are or prior to this Agreement were developed by RESprotect and which RESprotect is permitted to disclose to SciClone without violating any Third Party agreements. 
 SECTION 1.27 The term “RESprotect Patent Rights” shall mean any Patent Rights under U.S. Patent No. 6,589,941, a patent or patents issuing on U.S. patent applications published as 20040127454 and
20060178338 only to the extent they relate to RP 101 and any US and/or Canadian patents or patent applications claiming priority to, or directly related to, the above patents or patent applications filed by RESprotect only to the extent they relate
to RP 101. 
 SECTION 1.28 The term “SciClone Invention(s)” shall have the meaning set forth in Section 8.1. 
 SECTION 1.29 The term “Scale-Up Plan” shall have the meaning set forth in the 2007 Supply Agreement. 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	4	  	CONFIDENTIAL TREATMENT

 SECTION 1.30 The term “Sublicensee” shall mean any Affiliate of SciClone or Third Party who receives a
sublicense from SciClone relating to the License upon entering into any of the following agreements with SciClone: a sublicense agreement, research and development agreement, or alternative form of collaboration or commercialization agreement, such
as, but not limited to, a co-promotion or co-marketing arrangement to research, develop, import, make (subject to Article VI of this Agreement and the provisions of the 2007 Supply Agreement), use, offer for sale, and/or sell Licensed Product
in the Territory. 
 SECTION 1.31 The term “Territory” means the United States of America and Canada. 
 SECTION 1.32 The term “Third Party” shall mean any entity other than RESprotect or SciClone and their respective Affiliates. 
 SECTION 1.33 The term “USPTO” shall mean the United States Patent and Trademark Office 
 SECTION 1.34 The term “Valid Claim” shall mean a claim of an issued and unexpired patent within the RESprotect Patent Rights, which has not been held permanently revoked, unenforceable or invalid by a
decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise.

 ARTICLE II 
 GRANT
OF LICENSE/OPTION 
 SECTION 2.1 Grant of License Rights by RESprotect to SciClone. RESprotect hereby grants to SciClone the exclusive
license to use the RESprotect Patent Rights and the RESprotect Know-how to develop, use, make (subject to Article VI of this Agreement and the provisions of the 2007 Supply Agreement), have made (subject to Article VI of this Agreement and the
provisions of the 2007 Supply Agreement), sell, offer for sale and import the Licensed Product and Improvements under the RESprotect Patent Rights in the Territory (“License”). 
 SECTION 2.2 Sublicenses. SciClone shall have the right to grant sublicenses to the License to Sublicensees upon notification to RESprotect. Any such sublicense shall be at arm’s length and conform
to the terms hereof, and SciClone shall be responsible for the performance by its Sublicensee of all obligations imposed under the terms of this Agreement. 
 SECTION 2.3 [****] 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	5	  	CONFIDENTIAL TREATMENT

 ARTICLE III 
 PAYMENTS 
 SECTION 3.1 Milestone Payments. In consideration of the License provided hereunder, SciClone
shall compensate RESprotect by paying to RESprotect by wire transfer within fifteen (15) business days after the achievement of each of the milestones set forth below, the following payments: 
  

			
	Milestone	 	Payment to RESprotect
	Initiation of a Phase II Trial by SciClone or Sublicensees in the Territory or outside the Territory covering Licensed Product	 	$1.32 million US
		
	[****]	 	[****]
		
	[****]	 	[****]
		
	[****]	 	[****]

 Payments made by SciClone to RESprotect pursuant to this Section 3.1 are not refundable under
any circumstances, will not be credited against royalty payments due to RESprotect pursuant to Section 3 and apply as well in the event SciClone sublicenses to a Sublicensee. 
 SECTION 3.2 Royalties. Following the First Commercial Sale of a Licensed Product, SciClone will pay, on a calendar quarterly basis, without offset or deduction except as set forth in this Agreement, a
royalty in the amounts set forth in Section 3.3 below on Net Sales of the Licensed Product, as the case may be, during the previous quarter, calculated in U.S. Dollars. 
 SECTION 3.3 Royalty Calculation. 
 (a) In consideration of the License granted to SciClone,
SciClone shall pay to RESprotect a royalty at the rates set forth below of the Net Sales of Licensed Product sold by SciClone or its Sublicensees as follows: 
  

					
	Annual Market Sales	 	[****]	 	[****] of Net Sales
	Annual Market Sales	 	[****]	 	[****] of Net Sales

  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	6	  	CONFIDENTIAL TREATMENT

 (b) Royalty Payment Reports; Exchange Rates. During the term of this Agreement following the First
Commercial Sale of a Licensed Product, SciClone shall within forty-five (45) days after each calendar quarter pay to RESprotect the royalties due under the Agreement for such quarter and furnish to RESprotect a written quarterly report showing:
(i) the Market Sales of the Licensed Product sold by SciClone and its Sublicensees during the reporting period and the calculation of Net Sales from such Market Sales; (ii) the royalty due thereon; (iii) withholding taxes, if any,
required by law to be deducted in respect of such royalties (for the sake of clarification withholding taxes shall not be deducted from the Market Sales); and (iv) the exchange rates used in determining the amount of United States dollars. All
sales in currencies other than United States dollars shall be converted into United States dollars calculated at the exchange rate published in THE WALL STREET JOURNAL on the last day of the calendar quarter. If no royalty is due for any royalty
period hereunder, SciClone shall so report. SciClone shall keep complete and accurate records in sufficient detail to properly reflect all Market Sales and Net Sales to enable the royalties payable hereunder to be determined. 
 (c) Audits. Upon written request and advance notice of not less than thirty (30) days, SciClone shall permit an internal auditor or
independent public accountant selected by RESprotect and acceptable to SciClone, which acceptance shall not be unreasonably withheld or delayed, to have access during normal business hours to such records of SciClone as may be reasonably necessary
to verify the accuracy of the royalty reports described herein, in respect of any calendar year ending not more than thirty-six (36) months prior to the date of such request. All such verifications shall be conducted at RESprotect’s
expense and not more than once in each calendar year. In the event such RESprotect representative concludes, providing sufficient evidence, that additional royalties were owed to RESprotect during such period, the additional royalty shall be paid by
SciClone within thirty (30) days of the date RESprotect delivers to SciClone such representative’s written report so concluding. The fees charged by such representative shall be paid by RESprotect unless the audit discloses that the
royalties payable by SciClone for the audited period are underpaid by more than 5%, in which case SciClone shall pay the reasonable fees and expenses charged by such representative and a further amount equal to the amount of the additional royalty.
Any overpay will be refundable or credited against future royalties. SciClone shall include in each sublicense granted by it pursuant to this Agreement a provision requiring the Sublicensee to make reports to SciClone, to keep and maintain records
of sales made pursuant to such sublicense and to grant access to such records by RESprotect’s representatives to the same extent required of SciClone under this Agreement. RESprotect agrees that all information subject to review under this
Section 3.3(c) or under any sublicense agreement will be confidential and that RESprotect will cause its representatives to retain all such information in confidence. 
 SECTION 3.4 Form of Payment. 
 (a) Any milestone payment required to be made by SciClone to
RESprotect pursuant to the terms of Section 3.1, shall be made in U.S. Dollars. SciClone shall make each milestone payment in cash when due and payable by wire transfer in immediately available funds to an account designated by RESprotect
reasonably prior to the time of such payment. 
 (b) All royalties payable pursuant to Section 3.2 and 3.3 are calculated in U.S.
Dollars and all royalty payments made by SciClone to RESprotect will be paid in cash in US dollars ($) calculated on the basis of the exchange rate as published in THE WALL STREET JOURNAL on the last day of the calendar quarter. 
  

					
		  	7	  	CONFIDENTIAL TREATMENT

 SECTION 3.5 Third-Party License. 
 (a) In the event that a license from a Third Party [****] is necessary, in the sole opinion of SciClone, for SciClone to fully use the RESprotect Patent
Rights under the License, SciClone shall so inform RESprotect in writing and thereafter SciClone and RESprotect will cooperate in order to conclude a license agreement with the Third Party which is reasonably acceptable to SciClone and RESprotect.
RESprotect undertakes not to unreasonably withhold its acceptance and consent. The Parties shall also agree on who shall lead the negotiations with the Third Party, taking into consideration, inter alia, their respective experience and/or standing
with this Third Party, if any, and geographic, language and nationality advantages. In the event that upon the consent of RESprotect SciClone enters into a license agreement with a Third Party for the Territory and is obligated to pay royalties to
such Third Party [****], [****]. 
 [****] 
 However, in no event shall the royalties due to RESprotect under Section 3.3 of this Agreement be reduced to less than [****] of total Net Sales. 
 (b) [****] 
 (c) For the sake of clarification, this Section 3.5 does not apply in case SciClone
decides to take a Third Party license which has the purpose of combining the Licensed Product with [****]. For all costs related to any such Third Party license, SciClone shall bear the sole financial and commercial responsibility. 
 SECTION 3.6 Interest. Any late payment by SciClone shall bear interest at 2 percentage points over the 1 year LIBOR rate applicable at the time the payment
is made. 
 ARTICLE IV 
 SCICLONE’S DEVELOPMENT OBLIGATIONS 
 SECTION 4.1 SciClone Diligence. 
 (a) At its own cost and expense, SciClone shall conduct such clinical trials and apply for all governmental approvals necessary to manufacture (unless
otherwise provided herein), sell, market, and distribute Licensed Product, and to develop, submit regulatory applications for, manufacture and commercialize the Licensed Product (such activities cumulatively referred to as “Development”).
SciClone is fully committed to expediting the clinical development of the Licensed Product. To that end, SciClone will undertake the 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	8	  	CONFIDENTIAL TREATMENT

 
development of the Licensed Product according to Protocol Number RP101-II, incorporated in IND [****] (“Phase 2 Protocol”). The development plan
which is attached as Exhibit B (“Development Plan”) is a proposal by RESprotect for purposes of discussion at the first meeting of the Development Committee. SciClone and RESprotect agree to work diligently to complete the initial
Development Plan at the first meeting of the Development Committee. The Development Plan may be amended from time to time in response to additional clinical and non-clinical studies which may be required by the FDA. Topics related to the Development
Plan will be determined in the Development Committee (Section 4.2.) 
 (b) The parties acknowledge that lack of diligence in Development of
the Licensed Product will diminish the value of this Agreement to RESprotect; accordingly, SciClone shall at all times put forth good faith commercially reasonable efforts in connection with Development of the Licensed Product in the Territory.
SciClone agrees to make good faith commercially reasonable efforts and to use sound scientific judgment in Development of the Licensed Product; provided, however, that the parties understand and agree that the Development process and Development
Plan may from time to time be subject to reasonable adjustment by SciClone in coordination with RESprotect as set forth in Section 4.2. Any substantial deviation from the Development Plan shall be submitted to the Development Committee for
consideration and decision as set forth in Section 4.2. 
 (c) In addition, SciClone shall use good faith commercially reasonable
efforts and sound scientific judgment to fully exploit the Licensed Product to the extent of its commercial potential in the Territory. 
 (d) Subject to Section 4. l(b) above, the parties acknowledge and agree that all decisions including, without limitation, decisions relating to SciClone’ research, development, registration, manufacture (unless otherwise provided
herein), sale, commercialization, design, price, distribution, marketing and promotion of the Licensed Product in the Territory, shall be within the sole discretion of SciClone. Notwithstanding Section 4.1(b), nothing in this Agreement shall be
construed as imposing on SciClone the duty to market and/or sell and exploit Licensed Product for which royalties are payable hereunder to the exclusion of, or in preference to, any other product, or in any way other than in accordance with its
normal commercial practices and subject to Section 4.1(b) above. 
 SECTION 4.2 Development Committee. 
 (a) General. SciClone and RESprotect shall establish a Development Committee consisting of two representatives for each of SciClone and RESprotect.
The responsibilities of the Development Committee shall be to oversee the Development Plan and the Scale-up Plan and render periodic reports at least every calendar quarter covering the status of SciClone’ Development of Licensed Product,
RESprotect’s execution of the Scale-up Plan and related matters. The representatives of the Development Committee of SciClone and RESprotect shall be in a position to report on behalf of the represented parties about these matters. The
Development 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	9	  	CONFIDENTIAL TREATMENT

 Committee shall hold meetings at least one time every calendar quarter. The meetings may be conducted either in person or
by conference call; provided, however, that at least one meeting in each calendar year will be held in person in the United States at a location to be determined by the Development Committee. Each party shall bear its costs related to participation
on the Development Committee. The Development Committee shall also coordinate the development efforts by SciClone within the Territory and RESprotect’s scale-up efforts. RESprotect shall report to the Development Committee its development
efforts with regard to the Licensed Product outside the Territory unless it is prevented from this by law or by confidentiality or other agreements with Third Parties. 
 (b) Decision-Making. The Development Committee shall have the initial right to consider any adjustments of and deviation by SciClone from the Development Plan. If within thirty (30) days after submission,
the Development Committee does not reach a unanimous decision in the proposed change in the Development Plan, the proposed change in the Development Plan shall be submitted to the CEOs of SciClone and RESprotect for their consideration. If they do
not agree within thirty (30) days following submission of the proposed change by the Development Committee, SciClone shall have the right of final decision. 
 ARTICLE V 
 ACCESS TO CLINICAL TRIAL DATA 
 The results and other data from any preclinical and clinical trials (“Preclinical and Clinical Data”) undertaken by SciClone and/ or its
Sublicensees and/ or Third Parties in the United States or elsewhere in relation to the Licensed Product or otherwise generated in relation to this Agreement will be available at no cost for RESprotect for its research, regulatory and
commercialization purposes outside of the Territory. SciClone will share Preclinical and Clinical Data with RESprotect’s Other Licensees in Asia and Europe for their research, regulatory and commercialization purposes in their respective
territories on the following terms: (i) with respect to Asia, the Other Licensee will pay SciClone a fee equal to [****], and (ii) with respect to Europe, the Other Licensee will pay SciClone a fee equal to [****]; provided that SciClone
will have thirty (30) days to review and approve all regulatory filings or other use involving Third Parties of RESprotect and its Other Licensees which rely on Preclinical and Clinical Data to ensure that such regulatory filings or other use
involving Third Parties do not conflict with or otherwise adversely effect SciClone’s regulatory filings in the Territory, such approval to be provided in writing, not to be unreasonably withheld. The fee payable by RESprotect’s Other
Licensees for the Preclinical and Clinical Data will be due upon receipt of the Preclinical and Clinical Data by the RESprotect’s Other Licensee, and shall be payable in installments over a period of five years from the due date. Should a
RESprotect Other Licensee for 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	10	  	CONFIDENTIAL TREATMENT

 Europe and/or Asia license only part of the applicable territory, the [****] (for Asia) and [****] (for Europe) fee will
be adjusted in view of the actual market size of the particular territory versus the full market size of Asia or Europe, as applicable. Except as set forth above, neither RESprotect nor its permitted Other Licensees will share or otherwise transfer
Preclinical and Clinical Data to any Third Party without the prior written permission of SciClone. 
 ARTICLE VI 
 SUPPLY OF LICENSED PRODUCT; MANUFACTURE AND SUPPLY OF API 
 SECTION 6.1 Supply of Licensed Product for Clinical Trials. Until the appropriate application(s) are filed with the FDA and FDA approval of the Licensed Finished Product is obtained, it is agreed that
RESprotect will manufacture and supply SciClone with the Licensed Product as required by SciClone for conducting clinical trials and SciClone will purchase Licensed Product from RESprotect. The Licensed Product for Phase II Clinical Trials will be
supplied in [****], the Licensed Product for other phases of Clinical Trials will be supplied as API prior to tableting. The details of such purchase are set forth in the 2007 Supply Agreement. 
 SECTION 6.2 Supply of Licensed Product for Commercial Purposes. SciClone will purchase from RESprotect the Licensed Product which it requires for the
manufacture of the Licensed Finished Product after FDA approval of the Licensed Product. The details of such purchase are set forth in the 2007 Supply Agreement. 
 SECTION 6.3 [****] 
 ARTICLE VII 
 REPRESENTATIONS AND WARRANTIES 
 SECTION 7.1 Mutual Representations. SciClone and RESprotect
each represent and warrant to the other on the 2007 Effective Date as follows: 
 (a) Organization. It is a corporation duly organized,
validly existing and, as for SciClone, in good standing under the laws of the jurisdiction of its incorporation and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement. 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	11	  	CONFIDENTIAL TREATMENT

 (b) Authorization. The execution, delivery and performance by it of this Agreement has been duly
authorized by all necessary corporate action and does not violate any provision of any law, rule, regulation, order, writ, judgment, injunction, decree, determination or award presently in effect having applicability to it or any provision of its
charter documents or any agreement or other instrument or obligation to which it is bound or its assets are subject. 
 (c) Binding
Agreement. This Agreement is a legal, valid and binding obligation of it enforceable against it in accordance with its terms and conditions. 
 (d) No Inconsistent Obligation. It is not under any obligation to any person, or entity, contractual or otherwise, that is conflicting or inconsistent in any respect with the terms of this Agreement or that would impede the diligent
and complete fulfillment of its obligations hereunder. 
 SECTION 7.2 Representation of RESprotect regarding Title to Licensed Product; Mutual
Representation regarding Performance. 
 (a) RESprotect is the sole owner of the RESprotect Patent Rights and RESprotect Know-how, free
and clear of all liens, charges, encumbrances of Third Parties and RESprotect owns the exclusive, worldwide, royalty free, sublicensable, transferable right to use the Licensed Product under the RESprotect Patent Rights and RESprotect Know-how. To
RESprotect’s knowledge the patentability or validity of the RESprotect Patent Rights have not been contested or threatened to be contested by any Third Party and to RESprotect’s knowledge, there is no legitimate basis for such a claim. No
infringement proceedings have been initiated against Third Parties on the basis of the RESprotect Patent Rights. All patent applications which relate to the RESprotect Patent Rights have been filed in accordance with the applicable formal
requirements and none of such patent applications, or patents which cover the RESprotect Patent Rights have lapsed by reason of abandonment or non-payment of any fees. RESprotect has paid all maintenance fees, which are due and payable with respect
to the RESprotect Patent Rights through the date of signing of this Agreement. All patent applications, which relate to the RESprotect Patent Rights have been filed within the applicable period for claiming priority. To RESprotect’s knowledge,
RESprotect’s ownership of the RESprotect Patent Rights or its rights therein have not been contested or threatened to be contested by any Third Party. For the sake of clarification, RESprotect does not warrant that the RESprotect Patent Rights
are free from rights of Third Parties. However, to RESprotect’s knowledge, no Third Party has asserted or threatened to assert any rights in or to the RESprotect Patent Rights. 
 (b) To RESprotect’s knowledge, no other person or product infringes upon the Licensed Product in the Territory. 
 (c) RESprotect and SciClone are not in default (nor has there transpired an event which with notice or the lapse of time or both would be a default)
under any court order, agreement, document, instrument, indenture or other obligation of RESprotect or SciClone, respectively, which affects or could affect the use of the Licensed Product in the Territory or the performance of the respective party
under this Agreement. 
  

					
		  	12	  	CONFIDENTIAL TREATMENT

 (d) To RESprotect’s knowledge, there are no royalties, honoraria, fees or other payments payable by
RESprotect to any person by reason of RESprotect’s ownership in the RESprotect Patent Rights except for deferred payment obligations which arose in connection with (i) the acquisition of the RESprotect Patent Rights, US patent 6,589,941,
from the Fraunhofer-Gesellschaft in the year 2000, (ii) the subsidising of RESprotect by the Saechsische AufbauBank (“SAB”) and (iii) the employee invention compensation obligation of RESprotect relating to the RESprotect Patent
Rights, for all (i) to (iii) of which RESprotect shall have sole responsibility for timely payment. 
 (e) RESprotect has not
granted any right to a Third Party to use the Licensed Product under the RESprotect Patent Rights in the Territory. 
 (f) None of
RESprotect’s officers, directors, employees, consultants, agents or representatives have any ownership or other similar rights in or to the Licensed Product in the Territory. 
 SECTION 7.3 Knowledge. “Knowledge” or “known” shall mean, with respect to any representation or warranty or other statement in this Agreement qualified by positive knowledge of
RESprotect, the actual knowledge of Professor Fahrig. 
 ARTICLE VIII 
 INTELLECTUAL PROPERTY 
 SECTION 8.1 Ownership of SciClone Inventions and Joint
Technology. License. 
 It is expected that additional intellectual property may be created during performance under this Agreement. Any
inventions made solely by employees of SciClone or any of its Affiliates or Sublicensees during the performance of this Agreement (“SciClone Inventions”) shall be owned by SciClone. Joint Technology and any Patent Rights on Joint
Technology shall be owned jointly by SciClone and RESprotect at equal ratio. For any SciClone Invention directly related to an improved method of use of the Licensed Product, and only to the extent necessary for RESprotect to use the RESprotect
Patent Rights, SciClone shall grant RESprotect a non-exclusive, royalty-free, perpetual license outside the Territory, with the right to grant sublicenses (“Grant-Back License”). SciClone shall inform RESprotect of any SciClone Invention
promptly after it has been made. SciClone shall claim any inventions made by its employees. 
 SECTION 8.2 Patent Rights on Joint Technology.

 (a) RESprotect and SciClone will cooperate in the protection of Patent Rights and other intellectual property rights for Joint Technology.

 (b) All costs relating to preparation, prosecution and maintenance of Patent Rights on Joint Technology in the Territory shall be paid by
SciClone. SciClone shall have the first right, but not the obligation, to control, at its sole expense, the preparation, filing, prosecution and maintenance of all patents and patent applications claiming an Invention based on Joint Technology and
for conducting any interferences, re-examinations, reissues, oppositions, or requests for patent term extensions relating thereto in the 
  

					
		  	13	  	CONFIDENTIAL TREATMENT

 Territory, provided that it shall inform and coordinate any such acts with RESprotect duly in advance. SciClone shall
keep RESprotect informed of all filings related to such prosecution reasonably in advance of any relevant actions and deadlines and take reasonable account of all comments received from RESprotect in relation thereto. In the event that SciClone
elects not to prosecute or maintain any patent application or patent claiming an Invention based on Joint Technology in the Territory, it shall immediately inform RESprotect, and RESprotect shall have the right, at its option and sole expense, to
take over the filing, prosecution and/or maintenance of such patent or patent application and in that event SciClone shall transfer to RESprotect SciClone’s share in the Invention based on Joint Technology in the Territory free of costs.

 (c) All costs relating to preparation, prosecution and maintenance of Patent Rights on Joint Technology outside the Territory shall be
paid by RESprotect. RESprotect shall have the first right, but not the obligation, to control, at its sole expense, the preparation, filing, prosecution and maintenance of all patents and patent applications claiming an Invention based on Joint
Technology outside the Territory, provided that it shall inform and coordinate any such acts with SciClone duly in advance. RESprotect shall keep SciClone informed of all filings related to such prosecution reasonably in advance of any relevant
actions and deadlines and take reasonable account of all comments received from SciClone in relation thereto. In the event that RESprotect elects not to prosecute or maintain any patent application or patent claiming an Invention based on Joint
Technology in the Territory, it shall immediately inform SciClone, and SciClone shall have the right, at its option and sole expense, to take over the filing, prosecution and/or maintenance of such patent or patent application and in that event
RESprotect shall transfer to SciClone RESprotect’s share in the Invention based on Joint Technology in the Territory free of costs. 
 SECTION 8.3
Patent Rights on SciClone Inventions. 
 All costs relating to Patent Rights on SciClone Inventions will be borne by SciClone,
which will not have any responsibility for any costs relating to existing RESprotect Patent Rights and any new patents filed by RESprotect outside the Territory. If SciClone elects not to file or maintain Patent Rights for a particular SciClone
Invention in the Territory, SciClone shall inform RESprotect immediately, in any event prior to the expiry of any deadlines for the relevant action, and RESprotect shall have the right at its own expense to file, prosecute and maintain the patent
application/patent for that SciClone Invention. If RESprotect so elects, SciClone shall transfer to RESprotect at no costs its rights in the Patent Rights but only for that patent application/patent and shall execute any documents and issue any
declarations necessary to effect this transfer free of costs. 
 SECTION 8.4 RESprotect Patent Rights. 
 All costs relating to maintaining RESprotect Patent Rights will be borne by RESprotect. If RESprotect decides not to file or maintain Patent Rights on any
particular patent included in the RESprotect Patent Rights, RESprotect shall inform SciClone in writing and SciClone shall have the right at its own expense to file, prosecute and maintain patent applications or patents. If SciClone elects so,
RESprotect shall transfer its rights in such patent applications or patents to SciClone for the Territory and shall execute any documents and issue any declarations necessary to effect the transfer. RESprotect shall keep SciClone informed on an
ongoing 
  

					
		  	14	  	CONFIDENTIAL TREATMENT

 basis regarding prosecution of the patent applications and maintenance of the patents included in the RESprotect Patent
Rights. RESprotect shall keep SciClone informed of all filings related to such prosecution or maintenance reasonably in advance of any relevant actions and deadlines and shall consider in good faith without being obligated to the requests and
suggestions of SciClone with respect to strategies for filing, prosecuting, maintaining and extending the RESprotect Patent Rights. SciClone shall provide all assistance reasonably requested by RESprotect with respect to the filing, prosecution and
maintenance of the RESprotect Patent Rights. 
 SECTION 8.5 Notices of Infringement; Proceedings. 
 (a) Third Party Intellectual Property Rights. RESprotect and SciClone shall notify each other of any allegations by a Third Party that the activity
of either of the parties under this Agreement infringes or may infringe the intellectual property rights of such Third Party. Both parties will cooperate in good faith in defending all claims relating to patent infringement by use of the License by
SciClone. SciClone shall not have the right to settle any patent infringement litigation in a manner that diminishes the rights or interests of RESprotect to this Agreement or obligates RESprotect to make payment or take any action without
RESprotect’s prior written consent. For any patent infringement proceedings, which arose by virtue of RESprotect’s activities under this Agreement, in the event that such settlement would materially affect the rights of SciClone under the
License, RESprotect undertakes to liaise with SciClone before entering into a settlement agreement and will take into consideration SciClone interests in such settlement. If such settlement materially diminishes the scope of the RESprotect Patent
Rights, the parties agree to negotiate in good faith an adjustment of the License on commercially reasonable terms and conditions. SciClone will be responsible for the costs associated with defending all claims and settlement costs relating to
patent infringement in the Territory, [****]. 
 (b) RESprotect Patent Rights. SciClone shall notify RESprotect of any infringement or
threatened infringement of the RESprotect Patent Rights in the Territory it becomes aware of. RESprotect shall have the first right to initiate proceedings against such infringer at its expense and retain any damages awarded. SciClone may join such
proceedings, in which case the parties shall bear the costs of the proceedings and share any damages awarded in equal ratio. In any event SciClone shall assist RESprotect, if so requested by RESprotect, in the proceedings. If RESprotect declines to
prosecute any infringer in the Territory, SciClone shall have the right at its expense to commence an infringement action and to retain any damages awarded. If such infringement action materially diminishes the scope of the RESprotect Patent Rights,
the parties agree to negotiate in good faith an adjustment of the License on commercially reasonable terms and conditions. RESprotect shall be solely responsible for at its discretion to defend the RESprotect Patent Rights against nullity actions
and other challenges of the validity of the RESprotect Patent Rights. 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	15	  	CONFIDENTIAL TREATMENT

 (c) Patent Rights on Joint Technology. SciClone or RESprotect shall notify the other Party of any
infringement or threatened infringement of the Patent Rights based on Joint Technology in the Territory it becomes aware of. Both parties will cooperate in good faith in defending all claims relating to patent infringement, including that they will
agree on who will lead the defense in the infringement action. The party controlling a Third Party infringement action shall keep the other party reasonably informed of developments in any such action, including, to the extent permissible by law,
the state of any settlement negotiations and the terms of any offer related thereto. The party controlling any such action shall not settle such action or otherwise consent to an adverse judgment in such action that diminishes, dilutes or impairs
the rights or interests of the non-controlling party or the validity or enforceability of the Patent Rights based on Joint Technology, without the prior written consent of the non-controlling party, such consent not to be unreasonably withheld.

 ARTICLE IX 
 INDEMNIFICATION 
 SECTION 9.1 SciClone Indemnity Obligations. SciClone agrees to defend, indemnify and hold RESprotect,
its Affiliates and their respective directors, officers, employees and agents harmless against any and all claims, suits, losses, judgments, liabilities, damages, costs and fees (including but not limited to reasonable attorneys’ fees) and
expenses resulting from or arising out of the breach by SciClone or its Sublicensees, respectively, of its representations and warranties in Article VII or any other breach of this Agreement. 
 SECTION 9.2 RESprotect Indemnity Obligations. RESprotect agrees to defend, indemnify and hold SciClone, its Affiliates and their respective directors,
officers, employees and agents harmless against any and all claims, suits, losses, judgments, liabilities, damages, costs, fees (including but not limited to reasonable attorneys’ fees) and expenses resulting from or arising out of (i) the
breach by RESprotect of its representations and warranties in Article VII or (ii) any other breach of this Agreement. RESprotect’s indemnity obligation related to its supplying Licensed Product will be incorporated in the 2007 Supply
Agreement. 
 SECTION 9.3 Procedure. A party or any of its Affiliates or their respective employees or agents (the “Indemnitee”) that
intends to claim indemnification under this Article IX shall promptly notify the other party (the “Indemnitor”) of any loss, claim, damage, liability or action in respect of which the Indemnitee intends to claim such indemnification,
and the Indemnitor shall assume the defense thereof. The indemnity agreement in this Article IX shall not apply to amounts paid in settlement of any loss, claim, damage, liability or action vis-à-vis a Third Party if such settlement is
effected without the consent of the Indemnitor, which consent shall not be withheld unreasonably. The failure to deliver notice to the Indemnitor within a reasonable time after the commencement of any such action shall not relieve the Indemnitor of
any liability to the Indemnitee under this Article IX, provided such failure to deliver does not prejudice the Indemnitor’s right and ability to defend that claim. The Indemnitee and its employees and agents shall cooperate fully with the
Indemnitor and its legal representatives in the investigation of any action, claim or liability against Third Parties covered by this indemnification. 

					
		  	16	  	CONFIDENTIAL TREATMENT

 SECTION 9.4 RESprotect Insurance. RESprotect shall carry and maintain product liability insurance at its
expense, covering its obligation as manufacturer, for as long as it supplies Licensed Product to SciClone or any Sublicensee pursuant to the 2007 Supply Agreement executed by the parties unless such insurance is carried by the actual manufacturer of
Licensed Product. A certificate evidencing such insurance coverage and all renewals thereof shall be provided to SciClone upon its request. 
 SECTION 9.5
SciClone Insurance. SciClone shall carry and maintain product liability insurance at its expense, covering its use of the supplied Licensed Product and of the Licensed Finished Product during clinical trials and commercialisation.
SciClone undertakes to name RESprotect as an additional insured party to this insurance. A certificate evidencing such insurance coverage and all renewals thereof shall be provided to RESprotect upon its request. 
 ARTICLE X 
 TERM AND
TERMINATION 
 SECTION 10.1 Term. This Agreement will start on the 2007 Effective Date and remain in effect until the earlier to occur
as follows: 
 (a) for the shorter of [****] from the 2004 Effective Date or until expiry or invalidity of the last to expire Valid Claim
under the RESprotect Patent Rights, including any patent term extension for delays in regulatory proceedings; or 
 (b) until terminated
under Sections 10.2 or 10.3. 
 SECTION 10.2 Termination. 
 (a) If either party commits a material breach of this Agreement, the other party shall have the right to terminate this Agreement by giving written notice to the breaching party in sufficient detail to ascertain and
respond to the alleged breach. Termination shall take effect thirty (30) days after receipt of such notice unless the breach is corrected within the same time period, except as otherwise provided in Section 10.2(b) and (c). 
 (b) The provisions of Sections 10.2(a) above notwithstanding, if SciClone fails to comply with its obligations of Development and/ or its
obligations to exploit the License pursuant to Section 4.1 (subject to SciClones’ right of termination under Section 10.2(c)), then RESprotect shall have the right to give SciClone written notice thereof stating in reasonable detail
the particular failure(s). SciClone shall have a period of thirty (30) days from the receipt of such notice to meet with RESprotect to discuss the activities that are being pursued to address the failure of diligence. In any event, SciClone
shall initiate a program to address the failure of diligence within forty-five (45) days from SciClone’ receipt of such notice, and the period for SciClone to cure the lack of diligence shall not 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	17	  	CONFIDENTIAL TREATMENT

 be longer than one hundred twenty (120) days from SciClone’ receipt of such notices. If, after expiry of this
time, an independent expert selected by RESprotect, subject to the consent of SciClone which consent shall not be unreasonably withheld, determines that SciClone has failed to meet SciClone’ obligations under Sections 4.1 of this
Agreement, RESprotect shall have the right to terminate this Agreement and SciClone shall bear the costs of the independent expert. 
 (c)
SciClone may terminate this Agreement if, in its sole discretion, it determines to not develop, register or have developed or registered Licensed Product by giving RESprotect ninety (90) days written notice, however if such decision is not due
to purely scientific reasons, it may only terminate with hundred forty-five (145) days prior written notice to RESprotect. 
 (d) The
right of either party to terminate this Agreement as herein above provided shall not be affected in any way by its waiver of or failure to take action with respect to any previous default. Any such termination shall be without prejudice to any
further rights and remedies vested in the parties. 
 SECTION 10.3 Liquidation. Bankruptcy. Insolvency. If (i) one of the parties shall go
into liquidation, other than for the purpose of a bona fide reorganization, (ii) or a receiver or trustee be appointed for its property or estate, (iii) or if such party shall make an assignment for the benefit of its creditors,
(iv) or if such party files for a voluntary petition in bankruptcy or application for insolvency or is adjudged bankrupt or insolvent, and whether or not any of the aforesaid acts be the outcome of a voluntary act of that party, the other party
shall be entitled to terminate this Agreement forthwith by written notice to the first party. 
 SECTION 10.4 Effects of Termination.

 (a) Expiration Of The Agreement. Upon expiration of this Agreement pursuant to Section 10.1(a) the License and the Grant-back License
shall terminate immediately; (ii) SciClone shall at its expense transfer to RESprotect any documentation and materials it received from RESprotect under this Agreement and (iii) SciClone will make available to RESprotect any Preclinical
and Clinical Data not yet made available, subject to the provisions of Article V. 
 (b) Termination for material breach or Liquidation,
Bankruptcy, Insolvency of SciClone. If RESprotect terminates this Agreement because of a material breach by SciClone pursuant to Section 10.2(a) or (b), or pursuant to Section 10.3 then (i) the License shall terminate;
(ii) SciClone shall provide RESprotect with any documents, information, data and materials, including any Preclinical and Clinical Data relevant for the development, registration and commercialization of the Licensed Product in the Territory
and outside the Territory and shall execute any documents and issue any declarations necessary to this end; (iii) SciClone shall transfer its share in Joint Technology to RESprotect and RESprotect shall be the sole owner of Joint Technology;
(iv) the Grant-Back License shall survive the termination until expiry of the Patent Rights under the SciClone Invention and shall extend under the same conditions also to the Territory and (v) SciClone shall cease all sales of Licensed
Product and transfer to RESprotect, at its expense any documentation and materials it received from RESprotect under this Agreement as well as any stock of Licensed Product which is in its possession at the date of termination. 
  

					
		  	18	  	CONFIDENTIAL TREATMENT

 (c) Termination for material breach or Liquidation, Bankruptcy, Insolvency of RESprotect. If SciClone
terminates this Agreement because of a material breach by RESprotect pursuant to Section 10.2 (a), or pursuant to Section 10.3, then (i) the License (including the right to sublicense) will remain in effect on a royalty free, fully
paid basis in consideration of a one-time payment to RESprotect equal to US$[****] multiplied by the number of years then remaining until the expiration of the last to expire Valid Claim under the RESprotect Patent Rights; (ii) RESprotect shall
transfer its share in Joint Technology to SciClone and SciClone shall be the sole owner of Joint Technology; and (iii) the Grant Back License shall terminate. 
 (d) Termination upon decision of SciClone for scientific reasons. If SciClone terminates the agreement because it determines not to develop, register or have registered Licensed Product pursuant to Section 10.2
(c) for purely scientific reasons, Section 10.4 (a) shall apply. 
 (e) Termination upon decision of SciClone for other than
scientific reasons. If SciClone terminates the agreement because it determines not to develop, register or have registered Licensed Product pursuant to Section 10.2 (c) for other than purely scientific reasons, (i) the License
terminates; (ii) SciClone shall, at the request of RESprotect, allow RESprotect to continue any studies under preclinical or clinical trials (for the sake of clarification, RESprotect shall have the right, but not the obligation, to carry on
the preclinical/ clinical trials) and upon such request of RESprotect SciClone shall provide RESprotect with all and any documents, information, data and materials, including any Preclinical and Clinical Data which directly or indirectly relate to
the development, registration and commercialization of the Licensed Product (to the extent not yet made available), and take any action, including to assist RESprotect in finding a suitable CRO to continue the studies and shall execute any documents
and issue any declarations in order to enable RESprotect to carry on the preclinical/ clinical trials and register and commercialize the Licensed Product in the Territory itself or through partners; (iii) SciClone shall not be liable to
RESprotect for any reason whatsoever resulting from RESprotect’s utilization after termination of this Agreement of any information or documents returned to RESprotect following termination; (iv) SciClone shall transfer its share in Joint
Technology to RESprotect and RESprotect shall be the sole owner of Joint Technology; (v) the Grant-Back License shall survive the termination until expiry of the Patent Rights under the SciClone Invention and shall extend under the same
conditions also to the Territory; (vi) SciClone shall transfer to RESprotect, at its expense, any documentation and materials it received from RESprotect under this Agreement as well as any stock of Licensed Product which is in its possession
at the date of termination. 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	19	  	CONFIDENTIAL TREATMENT

 (f) In any event, any termination or expiration of this Agreement pursuant to Sections 10.1, 10.2
and 10.3, shall be without prejudice to: 
 (i) the confidentiality rights and obligations under Article XII that survive termination;

 (ii) any other remedies which either party may then or thereafter have hereunder; and 
 (iii) either party’s obligation to make any payments due pursuant to this Agreement which accrue prior to termination, and at the time of
termination, all such payments due shall be made in full within 45 days unless the parties agree otherwise. 
 ARTICLE XI 

FORCE MAJEURE 
 Neither
party shall be held liable or responsible to the other party nor be deemed to have defaulted under or be in breach of this Agreement for failure or delay in fulfilling or performing any term of this Agreement when such failure or delay is caused by
or results from causes beyond the reasonable control of the affected party, including but not limited to fire, floods, embargoes, war, acts of war (whether war is declared or not), insurrections, riots, civil commotions, strikes, lockouts or other
labor disturbances, act of God or acts, omissions or delays in acting by any governmental authority or the other party; PROVIDED, HOWEVER, that the party so affected shall use reasonable commercial efforts to avoid or remove such causes of
nonperformance, and shall continue performance hereunder with reasonable dispatch whenever such causes are removed. Either party shall provide the other party with prompt written notice of any delay or failure to perform that occurs by reason of
FORCE MAJEURE. The parties shall mutually seek a resolution of the delay or the failure to perform as noted above. 
 ARTICLE XII

 CONFIDENTIALITY 
 SECTION
12.1 Nondisclosure Obligations. 
 (a) General. Except as otherwise provided in this Article XII, during the term of this
Agreement and for a period of five (5) years thereafter, both parties shall maintain in confidence and use only for purposes specifically authorized under this Agreement (i) information and data received from the other party resulting from
or related to the development of the Licensed Product, including any RESprotect Know-how and (ii) all other information and data supplied by the other party under this Agreement. For purposes of this Article XII, information and data
described in clause (i) or (ii) shall be referred to as “Information”. 
 (b) Limitations. To the extent it is
reasonably necessary or appropriate to fulfill its obligations or exercise its rights under this Agreement, a party may disclose to its Affiliates, sublicensees, consultants, outside contractors and clinical investigators, 
  

					
		  	20	  	CONFIDENTIAL TREATMENT

 Information it is otherwise obligated under this Section 12.1 not to disclose on an need-to-know basis on conditions
that such entities or persons signed prior to the disclosure of the Information to them a written confidentiality agreement under which it undertakes to keep the Information confidential for the same time periods and to the same extent as such party
is required to keep the Information confidential; and a party or its Sublicensees may disclose such Information to government or other regulatory authorities to the extent that such disclosure is reasonably necessary to obtain Patent Rights or
authorizations to conduct clinical trials of, and to commercially market the Licensed Product. The obligation not to disclose Information shall not apply to any part of such Information that: (i) is or becomes part of the public domain other
than by unauthorized acts of the party obligated not to disclose such Information or its Affiliates or sublicensees; (ii) can be shown by written documents to have been disclosed to the receiving party or its Affiliates or sublicensees by a
Third Party, provided such Information was not obtained by such Third Party in violation of a confidentiality obligation vis-a-vis the disclosing party; (iii) prior to disclosure under this Agreement, was already in the possession of the
receiving party or its Affiliates or sublicensees, provided such Information was not obtained directly or indirectly from the other party under this Agreement pursuant to a confidentiality agreement; (iv) can be shown by written documents to
have been independently developed by the receiving party or its Affiliates without breach of any of the provisions of this Agreement; or (v) is disclosed by the receiving party pursuant to interrogatories, requests for information or documents,
subpoena, civil investigative demand issued by a court or governmental agency or as otherwise required by law, provided that the receiving party notifies the other party immediately upon receipt thereof and grants the disclosing party the
possibility to seek legal protection against such disclosure and limits the scope of disclosure to that portion of the Information that is legally required to be disclosed. Furthermore, the obligations not to disclose Information as set forth in
this Agreement shall not apply with regard to (i) the obligations under Section 3 of the purchase agreement between RESprotect and the [****] of 5/6 March 2001 as amended twice under which RESprotect must submit the final reports for
clinical trial phase II for the mentioned indications to have it examined by an external expert and (ii) the obligations of RESprotect under No. (9) of the amendment decree dated 15 April 2002 to the grant of subsidy decree dated
25 April 2001 by [****] (“[****]”) under which RESprotect is obligated to notify [****] of the grant of licenses to Third Parties and must immediately submit the respective agreements with the Third Party to the [****]. RESprotect
will ensure that in the event of disclosure of Information to [****] and/ or [****], [****] and/ or [****] will sign an undertaking to keep confidential the Information and limit the use of the Information to internal use and not to distribute the
Information outside of [****] and/ or [****] or publish the Information in any way. 
 SECTION 12.2 Terms. Publications. Press Release. 
 (a) Terms of this Agreement. Except as provided in Section 12.1(b) hereof, RESprotect and SciClone each agree not to disclose any terms or
conditions of this Agreement or the Agreement as such to any Third Party without the prior written consent of the other 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	21	  	CONFIDENTIAL TREATMENT

 party, except as required by applicable law or pursuant to a confidentiality agreement no less restrictive than this
Article XII. Each of SciClone and RESprotect will have the right to review, comment upon and approve any filings made by the other with any US or non-US securities regulators, such approval not to be unreasonably withheld. The Parties will
agree within 15 days from the Effective Date on a press release announcing the execution of this Agreement and each party shall be forthwith entitled to use this press release and similar press release with substantially the same language without
the consent of the other party. From time to time the Parties will agree on press releases announcing events related to this agreement and each party shall be forthwith entitled to use such press releases and similar press releases with
substantially the same language without the consent of the other party. 
 (b) Publications. Both parties recognize the mutual
interest in obtaining patent protection for inventions, which arise under this Agreement. In the event that employees or consultants or any other Third Party under contract to RESprotect or SciClone wishes to make a publication (including any oral
disclosure made without obligation of confidentiality) relating to work performed under this Agreement (the “Publishing Party”), the Publishing Party shall transmit to RESprotect and SciClone a copy of the proposed written publication at
least forty-five (45) days prior to submission for publication. RESprotect and SciClone shall have the right (a) to propose modifications to the publication for confidentiality reasons, (b) to request a delay in publication or
presentation in order to protect patentable information, or (c) to request that the information be maintained as a trade secret and, in such case, the Publishing Party shall not make such publication. 
 (c) Delay. If either RESprotect or SciClone requests a delay as described in Section 12.2(b), the Publishing Party shall delay submission or
presentation of the publication for a period of ninety (90) days from the request of RESprotect to enable patent applications protecting rights in such information to be filed. 
 (d) Resolution. Upon receipt of written approval of RESprotect, the Publishing Party may proceed with the written publication or the oral
presentation. 
 SECTION 12.3 Injunctive Relief. The parties hereto understand and agree that remedies at law may be inadequate to protect
against any breach of any provisions of this Article XII by either party or their employees, agents, officers or directors or any other person acting in concert with it or on its behalf. Accordingly, each party shall be entitled to the granting
of injunctive relief by a court of competent jurisdiction against any action that constitutes any such breach of this Article XII, without any requirement to post a bond. 
 ARTICLE XIII 
 MUTUAL COOPERATION; CORRECTIVE ROCEEDINGS 

SECTION 13.1 Cooperation. Each of the parties shall use its commercially reasonable efforts to take, or cause to be taken, all action or do or cause to
be done, and to assist and cooperate with each other party in doing, all things necessary, proper or advisable to consummate and make effective, in the most expeditious manner practicable, the transactions contemplated by this Agreement and any
further filings with relevant patent offices (in each case, to the extent that the same is within the control of such party). 
  

					
		  	22	  	CONFIDENTIAL TREATMENT

 SECTION 13.2 Corrective Proceedings 
 (a) Notwithstanding patent proceedings initiated by Third Parties, for which section 8.5 shall apply as the sole remedy, if, in the opinion of
SciClone’s patent counsel, prior art raises a substantial new question of patentability related to any of the patents from which the RESprotect Patent Rights are derived, SciClone shall provide notice thereof (“Corrective Proceeding
Notice”) to RESprotect. Within 10 days of receipt of the Corrective Proceeding Notice, RESprotect shall refer the matter to its patent counsel, who shall then confer with SciClone’s patent counsel. If RESprotect’s patent counsel
agrees with SciClone’s patent counsel that a substantial new issue of patentability has been raised by prior art, RESprotect’s patent counsel shall promptly provide notice thereof to RESprotect (“RESprotect Patent Counsel
Notice”). If RESprotect’s patent counsel does not agree with SciClone’s patent counsel, RESprotect shall promptly give notice thereof to SciClone and the question shall be submitted to an independent patent counsels with at least 20
years experience in the industry mutually selected by SciClone and RESprotect, or if they are unable or fail to select the independent patent counsel, by the American Arbitration Association. If the independent patent counsel, after considering the
positions of each of the respective patent counsel of SciClone and RESprotect, agrees with SciClone’s patent counsel, independent counsel shall promptly send notice thereof (“Independent Patent Counsel Notice”) to RESprotect with a
copy to SciClone. Within 90 days after receipt of the RESprotect Patent Counsel Notice or the Independent Patent Counsel Notice, as the case may be, RESprotect shall file the appropriate documentation with the USPTO to seek a reexamination or, if
deemed more appropriate by RESprotect, re-issue of the patent(s) cited in the Corrective Proceeding Notice. If independent patent counsel agrees with RESprotect’s patent counsel, independent counsel shall promptly send notice thereof to
SciClone, with a copy to RESprotect, and RESprotect shall not be required to take any further action with respect to the matter referred to in the subject Corrective Proceeding Notice. The costs of the independent patent counsel shall be borne by
RESprotect if such counsel agrees with SciClone’s patent counsel and by SciClone if such counsel agrees with RESprotect’s patent counsel. RESprotect shall have the right to control the prosecution of the corrective proceedings, including
but not limited to selecting the attorney or agent to prosecute the corrective proceedings at the USPTO. SciClone shall have the right to review and comment on all documents prior to the filing of such documents at the USPTO, which comments shall be
considered in good faith by RESprotect. RESprotect and SciClone shall share equally all costs incurred in connection with the filing and prosecution of any corrective proceeding, provided that if the prior art arises from any Patent Rights of
Newbiotics, RESprotect shall bear all costs of the corrective proceedings alone. 
 (b) RESprotect and SciClone agree to cooperate in every
way possible in obtaining evidence and going forward with such corrective proceedings. 
 (c) Each party shall promptly inform the other as
to all matters that come to its attention that may affect the corrective proceedings of the subject patent and permit each other to provide comments and suggestions with respect to the corrective proceedings, which comments and suggestions shall be
considered in good faith by the other party. 
  

					
		  	23	  	CONFIDENTIAL TREATMENT

 ARTICLE XIV 
 MISCELLANEOUS PROVISIONS 
 SECTION 14.1 Assignment. This Agreement may not be assigned or
otherwise transferred by either party to a Third Party without the prior written consent of the other party; PROVIDED, HOWEVER, that either party may, without such consent, assign its rights and obligations under this Agreement (i) in
connection with a corporate reorganization, to any Affiliate, all or substantially all of the equity interest of which is owned and controlled by such party or its direct or indirect parent corporation, or (ii) in connection with a merger,
consolidation or sale of substantially all of such party’s assets to an unrelated Third Party or a sale to an unrelated Third Party of all or a substantial portion of its business of which the transaction contemplated hereby is a part unless in
case of a merger, consolidation or sale made by either party where the Third Party is a competitor of the other party, in which case the merger, consolidation or sale shall require the prior written consent of the other party, which consent shall
not be unreasonably withheld or delayed. A “competitor” is defined as an organization which is developing a product for use to overcome chemotherapy resistance when used in combination with a chemotherapeutic agent. Competitors would not
include organizations which develop products that could be used in triple combination therapy regimens that include a chemotherapeutic agent plus BVDU but which are not used to overcome chemotherapy resistance. The assigning party’s rights and
obligations under this Agreement shall be assumed in writing by its successor in interest in any such transaction, and the assigning party shall inform the other party of the assignment without undue delay after the assignment. Any purported
assignment in violation of the preceding sentence shall be void unless later approved in writing by the other party. Any permitted assignee shall assume all obligations of its assignor under this Agreement. 
 SECTION 14.2 Notice. Any notice required or permitted hereunder shall be in writing and shall be sufficiently given when mailed postpaid first class
registered, certified mail or recognized overnight courier and addressed to the party for whom it is intended at its record address, and such notice shall be effective as of the date it is deposited in the mail. The record address of each party for
this purpose is its address set forth below: 
  

			
	If to SciClone:	  	 SciClone Pharmaceuticals, Inc.
 Attn: Richard Waldron

 901 Mariners Island Blvd., San Mateo, California 94404, USA
 Fax: 650-358-3469

		
	With a copy to:	  	 DLA Piper US LLP
 Attn: Howard Clowes
 153 Townsend Street, Suite 800
 San Francisco, California 94107,
USA

		
	If to RESprotect:	  	 RESprotect GmbH
 Attn.: Managing Director
 Fiedlerstr. 34
 D-01307 Dresden, GERMANY
 Fax: +49 (351) 4503210

  

					
		  	24	  	CONFIDENTIAL TREATMENT

			
	with a copy to:	  	 Mayer Brown Rowe and Maw LLP
 Attn. Dr. Rüdiger
Herrmann
 Bockenheimer Landstraße 98-100
 60323 Frankfurt
am Main
 Germany

 Each party may, at any time, substitute for its previous record address any other address by
giving prior written notice of the substitution. 
 SECTION 14.3 Governing Law. This Agreement shall be governed, interpreted and construed in
accordance with the laws of the State of New York, without regard to its choice of law provisions thereof; provided, however, that the scope, validity and enforceability of patents shall be determined in accordance with the applicable laws of the
countries in which such patents have been issued. 
 SECTION 14.4 Waiver. The failure of either party to insist upon the strict performance of
any provisions hereof or to exercise any right or remedy shall not be deemed a waiver of any right or remedy with respect to any existing or subsequent breach or default; the election by either party of any particular right or remedy shall not be
deemed to exclude any other; and all rights and remedies shall be cumulative. 
 SECTION 14.5 Severability. Each party hereby agrees that it
does not intend to violate any public policy, statutory or common laws, rules, regulations, treaty or decision of any government agency or executive body thereof of any country or community or association of countries. Should one or more provisions
of this Agreement be or become invalid, the parties hereto shall substitute, by mutual consent, valid provisions for such invalid provisions which valid provisions in their economic effect are sufficiently similar to the invalid provisions that it
can be reasonably assumed that the parties would have entered into this Agreement with such valid provisions. In case such valid provisions cannot be agreed upon, the invalidity of one or several provisions of this Agreement shall not affect the
validity of this Agreement as a whole, unless the invalid provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the parties would not have entered into this Agreement without the invalid provisions.

 SECTION 14.6 Dispute Resolution 
 (a) Good Faith Attempt to Resolve. The parties hereby agree that they will attempt in good faith to resolve any controversy or claim arising out of or relating to this Agreement promptly by negotiations. 
 (b) Arbitration. If the parties are unable to resolve the matter through negotiations, the parties shall submit the dispute to arbitration. The
arbitration shall be held in accordance with the Commercial Arbitration Rules of the American Arbitration Association (the “Arbitration Rules”), as the Arbitration Rules then exist by three arbitrators appointed in accordance with the

  

					
		  	25	  	CONFIDENTIAL TREATMENT

 Arbitration Rules. The arbitration shall take place in San Francisco, California if initiated by SciClone or Frankfurt,
Germany if initiated by RESprotect. Any decision or award resulting from the arbitration provided for herein shall be final and binding on the parties hereto. Judgment upon the arbitrator’s award may be entered in any court of competent
jurisdiction. Under no circumstances shall either party be obliged to use arbitration to reconcile RESprotect patent issues. The arbitrator shall have right to award costs, including reasonable attorneys’ fees, to the prevailing party in any
arbitration. 
 (c) Right to Seek Injunctive Relief. Notwithstanding the foregoing provisions of this Section 14.6, either party
has the right to bring suit in a court of competent jurisdiction against the other party for (i) any breach of such other party’s duties of confidentiality pursuant to Article XII of this Agreement and (ii) any infringement of
its intellectual property rights by the other party. 
 SECTION 14.7 No Other Proceedings. SciClone agrees not to initiate any proceedings to
challenge the validity of the RESprotect Patent Rights or the secrecy of the RESprotect Know-how unless this Agreement provides otherwise. 
 SECTION 14.8
Entire Agreement. This Agreement, the 2007 Supply Agreement together with the Exhibits, Schedules and Appendixes hereto and thereto, contains the entire understanding of the parties with respect to the subject matter hereof and thereof.
All express or implied agreements and understandings, either oral or written, heretofore made are superseded by this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by all parties
hereto. 
 SECTION 14.9 Headings. The captions to the several Articles and Sections hereof are not a part of this Agreement, but are merely
guides or labels to assist in locating and reading the several Articles and Section hereof. 
 SECTION 14.10 Independent Contractors. It is
expressly agreed that RESprotect and SciClone shall be independent contractors and that the relationship between the two parties shall not constitute a partnership, joint venture or agency. Neither RESprotect nor SciClone shall have the authority to
make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other, without the prior consent of the other party to do so. 
 SECTION 14.11 Exports. The parties acknowledge that the export of technical data, materials, or products is subject to the exporting party receiving any necessary export licenses and that the parties
cannot be responsible for any delays attributable to export controls, which are beyond the reasonable control of either party. SciClone and RESprotect agree not to export or re-export, directly or indirectly, any information, technical data, the
direct product of such data, samples or equipment received or generated under this Agreement in violation of any applicable export control laws or governmental regulations. SciClone and RESprotect agree to obtain similar covenants from their
licensees, sublicensees and contractors with respect to the subject matter of this Section 14.11. 
  

					
		  	26	  	CONFIDENTIAL TREATMENT

 SECTION 14.12 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. 
  

					
		  	27	  	CONFIDENTIAL TREATMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth above.

  

			
	SCICLONE INC.
		
	By:	 	 /s/ Friedhelm Blobel

	Name:	 	Friedhelm Blobel
	Title:	 	CEO and President
	
	RESPROTECT GmbH
		
	By:	 	 /s/ Rudolf Fahrig

	Name:	 	Rudolf Fahrig
	Title:	 	CEO

  

					
		  	28	  	CONFIDENTIAL TREATMENT

 Exhibit A 
 Asia and Europe 
 [****] 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	29	  	CONFIDENTIAL TREATMENT

 Exhibit B 
 Development Plan 
 [****] 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	30	  	CONFIDENTIAL TREATMENTSupply Agreement for Licensed Product

 EXHIBIT 10.19 
 CONFIDENTIAL PROVISIONS REDACTED 
 Supply Agreement 
 for Licensed Product 
 Between 
 SciClone Pharmaceuticals, Inc. 
 901 Mariners
Island Blvd. 
 Suite 205 
 San
Mateo, California 94404 
 United States of America 
 (hereinafter referred to as “SciClone”) 
 And 
 RESprotect GmbH 
 Fiedlerstrasse 34

 01307 Dresden 
 Germany

 (hereinafter referred to as “RESprotect”) 

					
		  		  	CONFIDENTIAL TREATMENT

 PREAMBLE 
  

	1.	RESprotect possesses certain intellectual property rights related to RP101 ((E)-5-(2-bromovinyl-)2’-deoxyuridine—also known as BVDU). 

  

	2.	Resistys Inc. (“Resistys”) and RESprotect entered into a license agreement dated as of September 13, 2004 (hereinafter the “2004 License Agreement”) whereby
Resistys obtained a license from RESprotect to, among other things, the use of the active pharmaceutical ingredient (“API”) RP101 ((E)-5-(2-bromovinyl-)2’-deoxyuridine—also known as BVDU), salts of BVDU or a prodrug of BVDU (if
developed by RESprotect) under the RESprotect Patent Rights (as further defined in the License Agreement), (hereinafter “Licensed Product”), for the purpose of developing and obtaining certain regulatory approval for the Licensed Product
in finished form (“Licensed Finished Product”). 

  

	3.	Resistys and RESprotect entered into a Supply Agreement for Clinical Trial Material dated September 13, 2004 (hereinafter the “2004 Supply Agreement”).

  

	4.	Pursuant to a non-binding Term Sheet, effective March 15, 2007, RESprotect, Resistys, Avantogen Limited (“Avantogen”), Avantogen Oncology Inc. (“AOI”) and
SciClone, agreed, among other things, to complete certain definitive agreements, including an assignment by Resistys and Avantogen to SciClone of the 2004 License Agreement and an assignment by Resistys to SciClone of the 2004 Supply Agreement.

  

	5.	On the Effective Date, Resistys and Avantogen assigned the 2004 License Agreement to SciClone and Resistys assigned the 2004 Supply Agreement to SciClone, with the consent of
RESprotect. 

  

	6.	On the Effective Date, RESprotect and SciClone, entered into an Amended and Restated License Agreement (the “2007 License Agreement”) setting forth amendments to certain
terms and conditions of the 2004 License Agreement. 

  

	7.	On the Effective Date, SciClone will pay to RESprotect US $365,474 in consideration for [****], currently in inventory, pursuant to the [****] Invoice No. 12688 (which
corresponds to RESprotect invoices designated 07/2006 and 08/2006). 

  

	8.	Under Article 6 of the 2007 License Agreement RESprotect agrees to manufacture and supply the quantities of Licensed Product as required for conducting clinical trials
(“Clinical Trials”) in order to obtain regulatory approval for the Licensed Product and the quantities of Licensed Product required for commercial purposes following regulatory approval. These supplies are the subject-matter of this
Agreement. 

  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

					
		  	2	  	CONFIDENTIAL TREATMENT

	9.	For the sake of clarification, the Licensed Product for Phase II Clinical Trials will be supplied in filled, finished [****] and all other supplies of Licensed Product for Clinical
Trials as well as Licensed Product for commercial purposes will be supplied as the untableted API. RESprotect and SciClone may choose to use the same tablet manufacturer to benefit from economies of scale. 

  

	10.	For the sake of further clarification, the terms of this Agreement independently cover: (1) the supply of the Licensed Product for Clinical Trial purposes; and
(2) commercial purposes, after approval of the Licensed Product by the FDA. 

  

	11.	In consideration of the premises and the mutual covenants and agreements contained herein, SciClone and RESprotect agree as follows, whereby in the following, capitalized terms not
otherwise defined herein shall have the meaning ascribed to them in the 2007 License Agreement. 

 ARTICLE I 

SUBJECT MATTER – MANUFACTURE AND SUPPLY OF LICENSED PRODUCT; 
 PAYMENT FOR PAST SUPPLY 
 Section 1.1 Pursuant to the terms and conditions of this Agreement,
SciClone shall purchase the Licensed Product that it has ordered from RESprotect, and RESprotect shall be obligated to manufacture or have manufactured, sell and deliver such quantities of Licensed Product as ordered by SciClone and confirmed by
RESprotect as needed for Clinical Trials until acceptance by the FDA of the first NDA or abbreviated NDA for registration of the Licensed Finished Product for any indication and SciClone shall purchase the Licensed Product that it has ordered from
RESprotect for commercial purposes, all as detailed herein. Other than the material needed for Phase II Clinical Trials which will be supplied in [****], the Licensed Product will be provided as the API prior to tableting. 
 Section 1.2 SciClone represents and warrants that it shall not use the Licensed Product for any other purposes or uses other than those set forth in
the 2007 License Agreement and this Agreement. 
 Section 1.3 SciClone undertakes that it shall purchase the entire amount of the
Licensed Product required for conducting Clinical Trials and commercial purposes from RESprotect, subject to the terms and conditions provided herein. 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	3	  	CONFIDENTIAL TREATMENT

 Section 1.4 The details of supplies, including prices for Licensed Product for Clinical Trials are
set forth below. The details of supplies, including prices for Licensed Product for commercial purposes shall be agreed upon between the Parties as soon as commercially practicable after the completion of the scale-up batches as mentioned in Article
2 and in the Scale-Up Plan, unless agreed otherwise. 
 Section 1.5 Effective with this Agreement, SciClone will pay to RESprotect US
$365,474 in consideration for [****], currently in inventory, pursuant to the [****] Invoice No. 12688 (which corresponds to RESprotect invoices designated 07/2006 and 08/2006). The payment shall be made within 30 days from the effective date
of this Agreement. Furthermore, effective with this Agreement SciClone shall pay to Resistys Inc. for payment to RESprotect the amount of US$49,761.00 outstanding under invoices of RESprotect 12/2006, 1/2007 and 2/2007. 
 Article II 
 SCALE-UP

 Section 2.1 Scale-Up for Supply of Licensed Product 
 a. Scale-Up Process. SciClone will purchase from RESprotect the Licensed Product which it requires for the manufacture of Licensed Finished Product prior to and after FDA approval of Licensed Finished Product.
RESprotect has subcontracted with, among others, [****] to manufacture the Licensed Product. SciClone and RESprotect acknowledge that the manufacture of the Licensed Product by RESprotect will require a scale-up period of approximately [****] and
the expenditure of considerable funds. SciClone and RESprotect agree to share [****] when such scale-up costs are incurred. The expected scale-up costs are set forth in Appendix 1. RESprotect agrees to provide SciClone with specific
manufacturing information and documents including certificates of analyses, batch records and all other documents as required for FDA filings, within thirty (30) days following a request for such specific manufacturing information by SciClone,
unless RESprotect is prevented from such provision by reason of a conflicting existing provision with a contract manufacturer of RESprotect. The details of the scale-up will be set forth in a plan (“Scale-Up Plan”) which shall be
determined by good faith agreement between RESprotect and SciClone. RESprotect and SciClone agree to cooperate in good faith to obtain detailed information regarding the manufacturing process and scale-up efforts by Third Party contractors of
RESprotect. 
 b. Scale-Up Efforts. The parties further acknowledge that RESprotect’s lack of diligence in timely accomplishing
the scale-up in preparation for a Clinical Trial will diminish the value of this Agreement to SciClone and RESprotect. Accordingly, RESprotect shall at all times put forth good faith commercially reasonable efforts in connection with accomplishing
the 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	4	  	CONFIDENTIAL TREATMENT

 scale-up of Licensed Product for Clinical Trials in accordance with the Scale-Up Plan; provided, however, that the
parties understand and agree that the timeline and estimated expenditures may from time to time be subject to reasonable adjustment by RESprotect in response to extenuating circumstances not in the complete control of RESprotect. Any deviation or
delay in the scale-up process under the Scale-Up Plan shall require consideration by the Development Committee as set forth in the 2007 License Agreement. The final right of decision on any delay or deviation in the scale-up process under the
Scale-Up Plan lies with RESprotect, except that any decision which leads to an increase of more than [****] of SciClone’s annual payment obligation pursuant to this Section 2.1b., or any delay of more than [****], which would significantly
diminish the value of the opportunity to SciClone as demonstrated by SciClone, shall require SciClone’s prior written consent. 
 c.
Scale-Up Costs. The payments to be made by SciClone to RESprotect for the scale-up shall be made on quarterly, pro rata and upfront basis as follows: SciClone shall make an upfront payment for the costs envisaged under the scale-up for the
subsequent calendar quarter within 15 days after the commencement of the respective calendar quarter. At the end of each calendar year the payment shall be compared with the actual costs incurred by RESprotect during that year. Any underpayments of
SciClone shall be settled by SciClone within 30 days after receipt of notice from RESprotect of such underpayment. Any excess payments of SciClone shall be used to settle SciClone upfront payment obligation for the following quarter(s) or, if there
is no further quarter to come, be re-paid to SciClone. 
 d. Scale-up Period Production and Supply. RESprotect shall deliver to
SciClone and any Sublicensee [****] of the Licensed Product derived by RESprotect under the Scale-up process (“Clinical Scale-up Batches”) [****]. The details of the supplies of the Clinical Scale-Up Batches shall be in accordance with the
provisions under Article 6 below. 
 e. Pre- and Post Scale-up Period Production. Before the [****] of each Clinical Scale-up Batch,
which is allocated to SciClone, is fully utilized, RESprotect agrees to supply SciClone or any Sublicensee of SciClone (“Sublicensee”) with additional quantities of Licensed Product and after the shares of the Clinical Scale-up Batches are
allocated, RESprotect agrees to supply SciClone or any Sublicensee with quantities of Licensed Product in accordance with orders received from SciClone or its Sublicensee. All such additional quantities of Licensed Product shall be shipped to
SciClone or its Sublicensee, as appropriate, in accordance with its written instructions at the expense of SciClone. The details of the supplies shall be in accordance with the provisions under Article 6 below. 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	5	  	CONFIDENTIAL TREATMENT

 ARTICLE III 
 SECOND PRODUCTION SOURCE 
 Section 3.1 Second Production Source. RESprotect and SciClone
are interested in saving costs with regard to the manufacture of the Licensed Product. However, RESprotect represents and SciClone acknowledges: (i) that the current manufacture and supply of Licensed Product is subject to Know-how of Third
Parties and licensed to RESprotect and that RESprotect is contractually bound to these Third Parties; (ii) that the manufacture process of Licensed Product is covered by RESprotect Know-how and (iii) that only sources located within [****]
are suitable as potential additional/alternative sources of supply of Licensed Product which sources must agree to supply exclusively (to the extent permitted by law) to RESprotect, SciClone and Sublicensees and (iv) that such supplier must
comply with the quality and quantity standards required by RESprotect, SciClone and Sublicensees and be cGMP compliant. If SciClone identifies a source of supply for Licensed Product complying to the aforementioned conditions above it will provide
RESprotect with written notice showing the conditions to be met, the costs of such source, the manufacture and quality standards of such source and authorizations and approvals it possesses, e.g. drug manufacture authorization. RESprotect undertakes
to review such submission in good faith within 30 days after receipt of the submission, taking into consideration inter alia its obligations vis-a-vis its existing suppliers, and to provide SciClone with a written opinion detailing whether
such alternative source of supply is acceptable to it in view of the above-mentioned preconditions. In any event, no contractual agreement shall be concluded with the potential alternative/additional source or any other obligation entered into with
this source which is binding upon RESprotect without the written consent of RESprotect, which shall not unreasonably withheld. 
 Section 3.2 Cheaper Second Production Source. Notwithstanding the foregoing, in the event that a source of supply of Licensed Product identified by SciClone can supply the Licensed Product at a price documented by a written and
bona fide offer that is at least [****], RESprotect shall have thirty (30) days to match the lower price or shall be deemed to have consented to SciClone’s use of that alternate production source, provided that SciClone, within thirty
(30) days after such consent has been deemed to be given, enters into a legally binding agreement with such source at identical terms and conditions as reflected in the written and bona fide offer of such source. RESprotect agrees to assist
SciClone in obtaining any necessary permissions to obtain Licensed Product directly from the lower priced production source, provided that to this end RESprotect is not obligated to make any payments to amend the contracts with its suppliers or to
breach any of the agreements with its suppliers. Notwithstanding the foregoing, RESprotect and SciClone agree to cooperate in good faith to obtain the most cost effective source of Licensed Product. To this end, RESprotect agrees to make
commercially reasonable efforts to obtain the Licensed Product in the most cost effective manner. 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	6	  	CONFIDENTIAL TREATMENT

 Section 3.3 Second Production Source upon Failure to Meet Scale-up Plan.  
 a. If RESprotect fails to substantially adhere to its obligations under the Scale-up process for Clinical Trial material as provided for in Article II,
then SciClone shall give written notice thereof to RESprotect stating in reasonable detail the particular failure(s). RESprotect shall have a period of thirty (30) days from the receipt of such notice to meet with SciClone to discuss the
activities that are being pursued to address the failure of diligence and to initiate a program to address the failure of diligence. Following such 30-day period RESprotect shall have a period of ninety (90) days to cure the lack of diligence
or, at its discretion, to find a second production source that is reasonably acceptable to SciClone and RESprotect and that complies with the requirements set forth in Section 3.1. 
 b. If RESprotect does not cure the failure within the aforementioned 90-day period and does not present a second production source to SciClone reasonably
acceptable to SciClone and complying with the conditions of Section 3.1(iii), SciClone shall have the right to request from RESprotect to enter into an agreement with a second production source for the Licensed Product, which is identified by
SciClone and satisfies the conditions of Section 3.1(iii). RESprotect agrees and acknowledges that a sublicense of the RESprotect manufacturing IP and know-how and those of its suppliers to SciClone is essential for transferring the production
of the Licensed Product to the second source and RESprotect agrees to assist SciClone in obtaining any necessary permissions, licenses or sublicenses required for SciClone to obtain the Licensed Product from a second production source alone or
together with RESprotect, provided that to this end RESprotect is not obligated to make any payments or to breach any of the agreements with its suppliers. RESprotect shall only be allowed to reject the second source presented by SciClone on the
following grounds: (i) it is not ensured that the second production source complies with the quality standards requested by the FDA and necessary to fulfill the product specifications for the Licensed Product established by RESprotect or does
not possess the necessary manufacture authorizations, (ii) exclusivity of supply (to the extent legally permissible) to RESprotect, its other licensees, SciClone and its Sublicensees is not ensured; (iii) the second source is not located
in the [****] (iv) the second source does not, at the reasonable determination of RESprotect, possess sufficient reputation in the market or technical capabilities, (v) it is not ensured that also RESprotect has access to the second source
and the second source will supply RESprotect and its other licensees (if RESprotect so requests), provided that in case of shortages of supply where a supply to both RESprotect and SciClone is not possible, the available supply shall be allocated
between the parties at a ratio reflecting the actual or projected sales of Licensed Finished Product by each party, further provided that in case the second source at the beginning of the scale up phase, for a maximum period of [****], is not able
to produce sufficient supply of Licensed Product to satisfy both RESprotect and SciClone needs, SciClone will have the prior right to satisfy its demand and thereupon RESprotect shall be supplied with the remaining (if any) stock, or
(vi) entering into an agreement with the second production source would violate any obligations of RESprotect vis-a-vis its current production source, especially in relation to the intellectual property rights of this production source.

  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	7	  	CONFIDENTIAL TREATMENT

 c. In case the second production source fails to satisfy the need for supply of Licensed Product for both
RESprotect and SciClone for a period exceeding the aforementioned [****] period then RESprotect shall be free to independently identify an alternative production source to satisfy its need for supply of Licensed Product at its cost and SciClone
shall resume all responsibility for the supply agreement with the second production source. 
 d. The costs of the second production source
under this section 3.3 (i.e. the costs of setting up the manufacture process and the costs of manufacture) shall either (i) be solely borne by SciClone and shall be credited against the requirement for Milestone Payments pursuant to
Section 3.1 and Royalties pursuant to Section 3.3 of the 2007 License Agreement, provided that the Milestone Payments or Royalties are due at the time the costs are incurred and shall be credited or (ii) be borne by SciClone and
RESprotect in proportion to the amount of Licensed Product actually supplied by the second production source to SciClone and RESprotect. For the avoidance of doubt, if the second source within the first [****] of the scale up phase does not supply
to RESprotect any amount of Licensed Product the cost of the second source shall be borne by SciClone as outlined in (i) above. 
 Section 3.4 Confidentiality; Cooperation by RESprotect. Any alternate production source permitted under Sections 3.2 and 3.3 shall enter into an appropriate confidentiality agreement covering RESprotect proprietary manufacturing
intellectual property and know-how and proprietary manufacturing intellectual property and know-how of other parties to which RESprotect is contractually bound to the extent RESprotect is under its agreements with its Third Party contractors allowed
to such disclosure. RESprotect agrees to facilitate and otherwise reasonably cooperate in the technology transfer process to the extent these activities do not constitute a breach by RESprotect under its agreements with Third Party contractors of
RESprotect and RESprotect shall have the right, at its sole expense and at reasonable times and with reasonable frequency, to inspect the manufacture of Licensed Product at such alternate production source. [****] 
 ARTICLE IV 
 SPECIFICATION OF
LICENSED PRODUCT 
 Section 4.1 The specifications of Licensed Product shall be based on the product specification described in the
IND [****] for the Licensed Product as attached hereto as Appendix 2 (“Product Specification”). 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	8	  	CONFIDENTIAL TREATMENT

 Section 4.2 If SciClone requests subsequent to the production of Licensed Product for the Phase II
Clinical Trials that RESprotect make modifications relating to Licensed Product Specification, including but not limited to a modified dosage form of Licensed Products, RESprotect agrees to use reasonable efforts to implement such modifications, if
possible. The costs, terms and conditions of such additional work shall be borne by SciClone. 
 ARTICLE V 
 PURCHASE PRICE OF LICENSED PRODUCT, TERMS OF PAYMENT AND 
 AUDITING 
 Section 5.1 Purchase Price of Licensed Product for Clinical Trials. The
purchase price for the Licensed Product for Clinical Trials ordered by SciClone in addition to [****] of the Clinical Scale-Up Batches derived by RESprotect under the scale-up process pursuant to Section 2.1d., shall be [****]. The expected
costs are set forth in Appendix 1 attached hereto and are subject to adjustment. The final costs of manufacture shall be determined after receipt of the final invoices of RESprotect’s suppliers and toll manufacturers. 
 Section 5.2 Purchase Price of Licensed Product for Commercial Purposes. The purchase price of the Licensed Product for commercial purposes
shall be agreed upon between the parties but shall in any event not be less than [****]. 
 Section 5.3 Currency Conversion. Late
Payment. Payment terms are net thirty (30) days from receipt of Licensed Product and invoice by SciClone. All payments must be made in US$. Currency conversion shall be made at the exchange rate as published in THE WALL STREET JOURNAL on
the day prior to the payment. Any late payment by SciClone shall bear interest at 2 percentage points over the 1 year LIBOR rate applicable at the time the payment is made. 
 Section 5.4 Documentation. Each invoice shall include a documentation of the costs of production or the purchase price to be paid by
RESprotect to its suppliers, the [****] and the transportation costs, taxes and insurance. 
 Section 5.5 Auditing. Upon written
request and advance notice of not less than thirty (30) days, RESprotect shall permit an internal auditor or independent public accountant selected by SciClone and acceptable to RESprotect, which acceptance shall not be unreasonably withheld or
delayed, to have access during normal business hours to such records of RESprotect as may be reasonably necessary to verify the accuracy of the invoiced purchase price for the Licensed Products, in respect of any calendar year ending not more than
thirty-six (36) months prior to the date of such request. These records shall, in particular include the bills 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	9	  	CONFIDENTIAL TREATMENT

 of the toll manufacturer. All such verifications shall be conducted at SciClone’s expense and not more than once in
each calendar year. In the event such SciClone’s representative concludes, providing sufficient evidence, that the invoiced amount for Licensed Products exceeds the purchase price as set forth in Section 5.1, RESprotect shall pay the
difference to SciClone within thirty (30) days of the date SciClone delivers to RESprotect such representative’s written report so concluding. The fees charged by such representative shall be paid by SciClone unless the audit discloses
that the excess costs of Licensed Product to be refunded by RESprotect for the audited period are more than 5% of the purchase price pursuant to Section 5.1, in which case RESprotect shall pay the reasonable fees and expenses charged by such
representative. SciClone agrees that all information subject to review under this Section will be confidential and that SciClone will cause its representatives to retain all such information in confidence. 
 Section 5.6 Title. Title to Licensed Product delivered shall be retained by RESprotect until the purchase price has been paid by SciClone.

 ARTICLE VI 
 ORDERS
AND SUPPLY 
 Section 6.1 For planning purposes of RESprotect, SciClone shall as soon as commercially practicable from the effective
date of this Agreement, provide RESprotect with an inspection plan for the Clinical Trials. SciClone shall place with RESprotect the orders for the quantity of Licensed Products required for the Clinical Trials. Each order shall become binding as
soon as RESprotect has confirmed the order in written form. Any confirmation, rejection or modified order proposal shall be provided to SciClone within fifteen (15) days of receipt of the order by RESprotect. RESprotect agrees to commence the
manufacture of a confirmed order immediately upon confirmation of the order. 
 Section 6.2 The delivery period for the Licensed Product
for Clinical Trials shall not exceed [****] as from the beginning of the manufacture of the Licensed Product. 
 ARTICLE VII 

 MANUFACTURE STANDARDS 
 Each
manufacture of Licensed Product shall be made in accordance with sound scientific methods and, applicable FDA guidelines and all Licensed Product supplied to SciClone or any Sublicensee by RESprotect will be manufactured in accordance with cGMP
(Good Manufacturing Practices), will be compliant with ICH guidelines and will be supported by appropriate documentation to enable a regulatory filing with the FDA and will meet the Product Specification for Licensed Product set forth in Article 4.

  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	10	  	CONFIDENTIAL TREATMENT

 ARTICLE VIII 
 SHIPMENT AND DELIVERY 
 Section 8.1 Shipment terms are EXW (ex works) as such term is defined in
INCOTERMS 2000 RESprotect’s facilities in Dresden or such other location that RESprotect designates. 
 Section 8.2 In the event of
any conflicting terms or conditions between any purchase order form, acknowledgement or invoice form of the parties, the terms and conditions of RESprotect shall prevail. 
 ARTICLE IX 
 INCOMING CONTROL; DEFECTS 
 Section 9.1 Upon receipt of the Licensed Product SciClone shall review Certificates of Analysis, batch records and other relevant documentation
pertaining to the Licensed Product, to ensure that the Licensed Product meets the Licensed Product Specifications as set forth in Article 4 above and to ensure conformity of quality and quantity of Licensed Product with the order. In the event that
upon such inspection SciClone identifies a damage or defect of Licensed Product, notification of such damage or defect shall be made to RESprotect in writing immediately, but in any event no later than fifteen (15) days after receipt of
Licensed Product by SciClone. If no such timely notification is made to RESprotect, Licensed Product shall be deemed to be accepted by SciClone and no claims can be made against RESprotect based on nonconformity of quality or quantity. 

Section 9.2 SciClone shall keep records for each inspection it carried out in accordance with Section 9.1 and shall provide RESprotect with
a copy of each record immediately after the respective inspection was carried out. SciClone shall retain the inspection records for the period of five years after the date of the respective inspection. RESprotect is responsible for the quality
control (QC) and quality assurance (QA) activities with respect to Licensed Product, not SciClone. RESprotect shall be responsible for ensuring that Licensed Product for Clinical Trials and commercial purposes is produced in compliance with cGMP
manufacture standards and that quality control (QC) and quality assurance (QA) is carried out by RESprotect’s suppliers in accordance with ICH standards to meet FDA regulatory filing requirements. 
 Section 9.3 In the case that upon incoming inspection, SciClone detects a defect and timely notifies RESprotect as set forth in Section 9.1,
RESprotect shall replace the defective Licensed Product free of charge to SciClone. SciClone shall return to RESprotect at the costs of RESprotect or at the request of RESprotect destroy the defective goods according to the applicable FDA
regulations and supply RESprotect with the corresponding certificate. RESprotect shall cover the costs of the destruction. Except for the aforementioned claims SciClone shall have no further claims against RESprotect for defective Licensed Product.

  

					
		  	11	  	CONFIDENTIAL TREATMENT

 ARTICLE X 
 WARRANTIES 
 RESprotect makes no warranties, express or implied, with respect to Licensed Product. Any warranties,
express or implied, including without limitation, the implied warranties of merchantability and fitness for a particular purpose are hereby disclaimed by RESprotect. 
 ARTICLE XI 
 LIABILITY, INDEMNIFICATION 
 Section 11.1 SciClone shall indemnify, defend and hold RESprotect, its directors, employees, agents and representatives harmless from and against
all claims, causes of action, settlement costs (including but not limited to reasonable attorney’s fees and expenses), losses or liabilities of any kind which arise from or are attributable to (i) any negligent or willful breach on the
part of SciClone, its employees, agents, representatives, Sublicensees or distributors of SciClone’s obligations under this Agreement; or (ii) the testing, use, handling, storage, purchase, sale or shipment of Licensed Product by SciClone,
its employees, agents, representatives, Sublicensees or distributors; and (iii) which are not otherwise attributable to a defect in Licensed Product for which RESprotect is liable pursuant to Article 9.3, nor are otherwise attributable to any
grossly negligent or willful misconduct on the part of RESprotect, its directors, employees, agents or representatives subject to the limitations set forth in Article 10. 
 Section 11.2 The obligations set forth in Section 11.1 shall apply during the term of this Agreement and for a period of five (5) years after the date of termination of this Agreement. 
 ARTICLE XII 
 LIMITATION ON
LIABILITY 
 Section 12.1 Subject to Section 11.1, each party shall be liable for damages resulting from the gross negligence
or willful misconduct of that party. 
 Section 12.2 Notwithstanding Section 11.1, liability of each party under this Article 12
shall be limited to such damages as were foreseeable for the liable party at the time of entering into this Agreement in terms of type and scope and the liability shall not include any indirect or consequential losses, lost revenues or lost profits.

 Section 12.3 Sections 12.1 and 12.2 shall also apply to any liability of the employees, agents and representatives of either party to
the other party. 
  

					
		  	12	  	CONFIDENTIAL TREATMENT

 ARTICLE XIII 
 TERM AND TERMINATION 
 Section 13.1 This Agreement shall enter into force upon signing and shall
terminate at the earlier of (i) the termination of the 2007 License Agreement unless the parties agree otherwise, (ii) the final termination by SciClone of all development, clinical and commercialization activities with respect to the
Licensed Product or the Licensed Finished Product, or (iii) termination pursuant to the provisions of Section 13.2 or 13.3 below. Notwithstanding the foregoing, any provisions of this Agreement relating to the supply of Licensed Product
for Clinical Trials shall terminate at the end of all Clinical Trials and/or studies for which the Licensed Product is used in order to develop and obtain regulatory approval for the Licensed Product. 
 Section 13.2 Either party may terminate this Agreement 
 a. by giving the other party sixty (60) days prior written notice upon the material breach of any provision of this Agreement by the other party if the breach is not remedied prior to the expiration of such sixty
(60) day notice period, subject to Section 13.3 below; 
 b. upon the bankruptcy or insolvency of the other party. 
 Section 13.3 The provisions of Section 13.1 and 13.2(b) above notwithstanding, if RESprotect fails to comply with its obligations of Scale-up
pursuant to Section 2, then SciClone shall have the right to give RESprotect written notice thereof stating in reasonable detail the particular failure(s). RESprotect shall have a period of thirty (30) days from the receipt of such notice
to meet with SciClone to discuss the activities that are being pursued to address the failure of diligence and initiate a program to address the failure of diligence. The period for RESprotect to cure the lack of diligence or present a second
production source to SciClone which complies with the requirements set forth in Section 3.1(iii) shall not be longer than one hundred twenty (120) days from RESprotect’s receipt of such notices. If, within this time RESprotect has not
cured the failure or presented a second production source to SciClone which is reasonably acceptable to SciClone and complies with the requirements of Section 3.1(iii) above, and SciClone within one hundred twenty (120) days after this
time, does not present a second source which is acceptable to RESprotect in accordance with Section 3.3(b), SciClone shall have the right to terminate this Agreement. 
 Section 13.4 The termination of this Agreement leaves unaffected the obligation of SciClone to pay for orders for Licensed Product placed prior to
such termination. SciClone shall be entitled to sell off any stock of Licensed Product in possession of SciClone at the time of termination of this Agreement for a further period of 6 (six) months from the effective date of the termination of this
Agreement, except in the event of a termination by RESprotect for material breach of SciClone pursuant to Section 13.2a. 
 Section 13.5 Notwithstanding any provisions in the 2007 License Agreement should RESprotect decide, at its sole, discretion, after termination of this Agreement to continue with any clinical development discontinued by SciClone
pursuant to Section 13.1, it 
  

					
		  	13	  	CONFIDENTIAL TREATMENT

 shall be entitled to request from SciClone re-transfer of the Licensed Products (including release documentation)
supplied to SciClone [****]. 
 ARTICLE XIV 
 FORCE MAJEURE 
 Neither party shall be held liable or responsible to the other party nor be deemed to have defaulted
under or be in breach of this Agreement for failure or delay in fulfilling or performing any term of this Agreement when such failure or delay is caused by or results from causes beyond the reasonable control of the affected party, including but not
limited to fire, floods, embargoes, war, acts of war (whether war is declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, act of God or acts, omissions or delays in acting by any governmental
authority or the other party; provided, however, that the party so affected shall use reasonable commercial efforts to avoid or remove such causes of non-performance, and shall continue performance hereunder with reasonable dispatch whenever such
causes are removed. Either party shall provide the other party with prompt written notice of any delay or failure to perform that occurs by reason of force majeure. The parties shall mutually seek a resolution of the delay or the failure to perform
as noted above. 
 ARTICLE XV 
 NONDISCLOSURE OBLIGATIONS 
 Section 15.1 Except as otherwise provided in this Article XV, during the term of this
Agreement and for a period of five (5) years thereafter, both parties shall maintain in confidence and use only for purposes specifically authorized under this Agreement or the 2007 License Agreement (i) information and data received from
the other party resulting from or related to the development of the Licensed Product, including any RESprotect Know-How and (ii) all other information and data supplied by the other party under this Agreement. For purposes of this Article XV,
information and data described in clause (i) or (ii) shall be referred to as “Information”. 
 Section 15.2
Limitations. To the extent it is reasonably necessary or appropriate to fulfill its obligations or exercise its rights under this Agreement, a party may disclose to its Affiliates, licensees, sublicensees, consultants, outside contractors and
clinical investigators, Information it is otherwise obligated under this Article XV not to disclose, on an need-to-know basis in accordance with the purposes of this Agreement on conditions that such entities or 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	14	  	CONFIDENTIAL TREATMENT

 persons signed prior to the disclosure of the Information to them a written confidentiality agreement under which it
undertakes to keep the Information confidential for the same time periods and to the same extent as such party is required to keep the Information confidential; and a party or its sublicensees may disclose such Information to government or other
regulatory authorities to the extent that such disclosure is reasonably necessary to conduct Clinical Trials of, and to commercially market the Licensed Product. The obligation not to disclose Information shall not apply to any part of such
Information that: (i) is or becomes part of the public domain other than by unauthorized acts of the party obligated not to disclose such Information or its Affiliates or sublicensees; (ii) can be shown by written documents to have been
disclosed to the receiving party or its Affiliates or sublicensees by a Third Party, provided such Information was not obtained by such Third Party in violation of a confidentiality obligation vis-a-vis the disclosing party; (iii) prior to
disclosure under this Agreement, was already in the possession of the receiving party or its Affiliates or sublicensees, provided such Information was not obtained directly or indirectly from the other party under this Agreement pursuant to a
confidentiality agreement; (iv) can be shown by written documents to have been independently developed by the receiving party or its Affiliates without breach of any of the provisions of this Agreement; or (v) is disclosed by the receiving
party pursuant to interrogatories, requests for information or documents, subpoena, civil investigative demand issued by a court or governmental agency or as otherwise required by law, provided that the receiving party notifies the other party
immediately upon receipt thereof and grants the disclosing party the possibility to seek legal protection against such disclosure and limits the scope of disclosure to that portion of the Information that is legally required to be disclosed.

 ARTICLE XVI 
 MISCELLANEOUS 
 Section 16.1 No alteration, amendment or modification to this Agreement shall be of any force and
effect unless made in writing and signed by the parties. 
 Section 16.2 No waiver of either party of strict compliance with any term(s)
and condition(s) of this Agreement shall constitute a waiver of any subsequent failure of the other party to strictly comply with each and every term and condition hereof. 
 Section 16.3 Should one or several provisions of this Agreement be or become invalid or unenforceable, then the parties hereto shall substitute such
provisions by valid ones, which in their economic effect come so close to the invalid or unenforceable provisions that it can be reasonably assumed that the parties would have contracted this Agreement also with those new provisions. The same
provision applies mutatis mutandis if a gap is found which requires regulation. In case such new provisions cannot be found, the invalidity or unenforceability of one or several provisions of this Agreement shall not affect the validity of the
Agreement as a whole, unless the invalid or unenforceable provisions are of such essential importance for this Agreement that it is to be reasonably assumed that the parties would not have contracted this Agreement without them. 
  

					
		  	15	  	CONFIDENTIAL TREATMENT

 Section 16.4 Assignment. This Agreement may not be assigned or otherwise transferred by
either party to a Third Party without the prior written consent of the other party; PROVIDED, HOWEVER, that either party may, without such consent, assign its rights and obligations under this Agreement (i) in connection with a corporate
reorganization, to any Affiliate, all or substantially all of the equity interest of which is owned and controlled by such party or its direct or indirect parent corporation, or (ii) in connection with a merger, consolidation or sale of
substantially all of such party’s assets to an unrelated Third Party or a sale to an unrelated Third Party of all or a substantial portion of its business of which the transaction contemplated hereby is a part, unless in case of a merger,
consolidation or sale made by either party where the Third Party is a competitor of the other party, in which case the merger, consolidation or sale shall require the prior written consent of the other party, which consent shall not be unreasonably
withheld or delayed. A “competitor” is defined as an organization which is developing a product for use to overcome chemotherapy resistance when used in combination with a chemotherapeutic agent. Competitors would not include organizations
which develop products that could be used in triple combination therapy regimens that include a chemotherapeutic agent plus BVDU but which are not used to overcome chemotherapy resistance. The assigning party’s rights and obligations under this
Agreement shall be assumed in writing by its successor in interest in any such transaction, and the assigning party shall inform the other party of the assignment without undue delay after the assignment. Any purported assignment in violation of the
preceding sentence shall be void unless later approved in writing by the other party. Any permitted assignee shall assume all obligations of its assignor under this Agreement. 
 Section 16.5 Notice. Any notice required or permitted hereunder shall be in writing and shall be sufficiently given when mailed postpaid
first class registered, certified mail or recognized overnight courier and addressed to the party for whom it is intended at its record address, and such notice shall be effective as of the date it is deposited in the mail. The record address of
each party for this purpose is its address set forth below: 
  

			
	 If to SciClone:
	 	 SciClone Pharmaceuticals, Inc.
 Attn: Richard Waldron

 901 Mariners Island Blvd., San Mateo, California 94404, USA
 Fax: 650-358-3469

		
	 With a copy to:
	 	 DLA Piper US LLP
 Attn: Howard Clowes,
 153 Townsend Street, Suite 800
 San Francisco, California 94107,
USA

		
	 If to RESprotect:
	 	 RESprotect GmbH
 Attn.: Managing Director
 Fiedlerstr. 34
 D-01307 Dresden, GERMANY
 Fax: +49 (351) 4503210

  

					
		  	16	  	CONFIDENTIAL TREATMENT

			
	with a copy to:	 	 Mayer Brown Rowe and Maw LLP
 Attn. Dr. Rüdiger
Herrmann
 Bockenheimer Landstraße 98-100
 60323 Frankfurt
am Main
 Germany

 Each party may, at any time, substitute for its previous record address any other address by giving prior written
notice of the substitution. 
 Section 16.6 Governing Law. This Agreement shall be governed, interpreted and construed in
accordance with the laws of Germany, without regard to its choice of law provisions thereof. 
 Section 16.7 Waiver. The failure
of either party to insist upon the strict performance of any provisions hereof or to exercise any right or remedy shall not be deemed a waiver of any right or remedy with respect to any existing or subsequent breach or default; the election by
either party of any particular right or remedy shall not be deemed to exclude any other; and all rights and remedies shall be cumulative. 
 Section 16.8 Dispute Resolution 
 a. Good Faith Attempt to Resolve. The parties hereby agree that they will
attempt in good faith to resolve any controversy or claim arising out of or relating to this Agreement promptly by negotiations. 
 b.
Arbitration. If the parties are unable to resolve the matter through negotiations, the parties shall submit the dispute to arbitration. The arbitration shall be held in accordance with the Commercial Arbitration Rules of the American
Arbitration Association (the “Arbitration Rules”), as the Arbitration Rules then exist by three arbitrators appointed in accordance with the Arbitration Rules. The arbitration shall take place in San Francisco, California if initiated by
SciClone or Frankfurt, Germany if initiated by RESprotect. Any decision or award resulting from the arbitration provided for herein shall be final and binding on the parties hereto. Judgment upon the arbitrator’s award may be entered in any
court of competent jurisdiction. Under no circumstances shall either party be obliged to use arbitration to reconcile RESprotect patent issues. The arbitrator shall have right to award costs, including reasonable attorneys’ fees, to the
prevailing party in any arbitration. 
 c. Right to Seek Injunctive Relief. Notwithstanding the foregoing provisions of this
Section 16.8, either party has the right to bring suit in a court of competent jurisdiction against the other party for (i) any breach of such other party’s duties of confidentiality pursuant to Article 15 of this Agreement.

 Section 16.9 Entire Agreement. This Agreement, the 2007 License Agreement and the schedules, exhibits and appendixes attached
hereto and thereto contains the entire understanding of the parties with respect to the subject matter hereof and thereof. All express or implied agreements and understandings, either oral or written, heretofore made are superseded by this
Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by all parties hereto. The 2004 Supply Agreement is hereby superseded and replaced in its entirety by this Agreement as of the
Effective Date. 
  

					
		  	17	  	CONFIDENTIAL TREATMENT

 Section 16.10 Independent Contractors. It is expressly agreed that RESprotect and SciClone
shall be independent contractors and that the relationship between the two parties shall not constitute a partnership, joint venture or agency. Neither RESprotect nor SciClone shall have the authority to make any statements, representations or
commitments of any kind, or to take any action, which shall be binding on the other, without the prior consent of the other party to do so. 
 Section 16.11 Exports. The parties acknowledge that the export of technical data, materials, or products is subject to the exporting party receiving any necessary export licenses and that the parties cannot be responsible for
any delays attributable to export controls, which are beyond the reasonable control of either party. SciClone and RESprotect agree not to export or re-export, directly or indirectly, any information, technical data, the direct product of such data,
samples or equipment received or generated under this Agreement in violation of any applicable export control laws or governmental regulations. SciClone and RESprotect agree to obtain similar covenants from their licensees, sublicensees and
contractors with respect to the subject matter of this Section 16.11. 
 Section 16.12 Conflicting Provisions. In the event
that any provisions of this Agreement conflict with any provisions under the 2007 License Agreement, the provisions of the 2007 License Agreement shall prevail. 
 Section 16.13 Defined Terms. Capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the 2007 License Agreement. 
 Section 16.14 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. 
  

					
	Dresden, 4/25/2007	 		 	San Mateo, CA, April 25, 2007
			
	 /s/ Rudolf Fahrig
	 		 	 /s/ Friedhelm Blobel

	RESprotect GmbH	 		 	SciClone Pharmaceuticals, Inc.
			
	Name: Rudolf Fahrig	 		 	Name: Friedhelm Blobel
			
	Position: CEO	 		 	Position: CEO and President

  

					
		  	18	  	CONFIDENTIAL TREATMENT

 Appendix 1 
 Scale-up Costs 
 [****] 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	19	  	CONFIDENTIAL TREATMENT

 Appendix 2 
 Product Specification for the Licensed Product 
 As specified in IND [****]. 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

					
		  	20	  	CONFIDENTIAL TREATMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}]]